

Review

# Potential Pharmacological Applications of *Nigella* Seeds with a Focus on *Nigella sativa* and Its Constituents against Chronic Inflammatory Diseases: Progress and Future Opportunities

Shadma Wahab \*  and Abdulrhman Alsayari 

Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha 62529, Saudi Arabia; alsayari@kku.edu.sa

\* Correspondence: sabdulwahab@kku.edu.sa

**Abstract:** The leading cause of death worldwide has been identified as chronic illnesses, according to the World Health Organization (WHO). Chronic inflammatory conditions such as asthma, cancer, diabetes, heart disease, and obesity account for three out of every five deaths. Although many people benefit from using nonsteroidal anti-inflammatory medicines (NSAIDs) for pain and inflammation relief, there are significant adverse effects to using these medications. Medicinal plants possess anti-inflammatory properties with minimal or no side effects. *Nigella sativa* (NS), also known as black cumin, is one of the plants used in traditional medicine the most. Many studies on the NS have shown that their therapeutic properties are attributed to the seed, oil, and secondary metabolites. This plant has been studied extensively and has many medical uses, such as anti-inflammatory. NS or its phytochemical compounds, such as thymoquinone, can cause cell apoptosis via oxidative stress, block efflux pumps, enhance membrane permeability, and exert potent biocidal effects. Notwithstanding the extensively documented anti-inflammatory effectiveness observed in the experimental model, the precise mechanisms underlying its anti-inflammatory effects in diverse chronic inflammatory diseases and its multi-targeting characteristics remain largely unexplored. This review examines NS or its secondary metabolites, a valuable source for the therapeutic development of chronic inflammatory diseases. Most clinical studies were done for diabetes and cardiovascular disease; therefore, more studies are required to examine the NS extracts and phytoconstituents to treat cancer, obesity, diabetes, asthma, neurological disorders, and COVID-19. This study will be a significant resource for clinicians and biologists seeking a pharmaceutical solution for inflammatory diseases.

**Keywords:** *Nigella sativa*; phytochemistry; bioactive molecules; chronic inflammatory diseases; toxicology



**Citation:** Wahab, S.; Alsayari, A. Potential Pharmacological Applications of *Nigella* Seeds with a Focus on *Nigella sativa* and Its Constituents against Chronic Inflammatory Diseases: Progress and Future Opportunities. *Plants* **2023**, *12*, 3829. <https://doi.org/10.3390/plants12223829>

Academic Editors: Isela Álvarez-González and Eduardo Madrigal-Bujaidar

Received: 17 October 2023  
Revised: 6 November 2023  
Accepted: 8 November 2023  
Published: 11 November 2023



**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

The World Health Organization (WHO) has identified chronic illnesses as the leading cause of death worldwide. Pro and anti-inflammatory endogenous mediators work in concert to eliminate harmful stimuli through the protective biological processes known as inflammatory responses. Chronic inflammatory illnesses, such as asthma, cancer, diabetes, heart disease, and obesity, account for three out of every five deaths [1]. Herbs as a therapeutic intervention for various ailments may be traced back to ancient periods predating recorded history. These drugs have been used to treat and prevent a wide variety of illnesses, including persistent inflammatory disorders. Although many people benefit from using nonsteroidal anti-inflammatory medicines (NSAIDs) for pain and inflammation relief, there are significant drawbacks to using these medications. There are few to no negative consequences from using medicinal herbs for their anti-inflammatory properties [2]. The usage of medicinal plants has increased despite the introduction of pharmacological drugs for treating chronic disorders. Numerous chronic illnesses have emerged due to the rapid changes in human lifestyle and diet that have taken place during

the last century. Natural drug use is again a hot subject, as synthetic medication effectiveness declines and new risks emerge. Therefore, researching phytotherapy to treat chronic illnesses may pay off handsomely in terms of potential sources of medicinal plants essential to disease prevention, and whose use and promotion align with all currently practiced preventive methods.

Although many ancient practices have died out in modern Western societies, some are still used by alternative medicine advocates or as complementary treatments. One of the plants used in traditional medicine to control chronic inflammatory ailments is *Nigella sativa* (NS). NS, also called black cumin, black seed, black caraway, fennel flower, Roman coriander or kalonji. This annual plant of the Ranunculus family (Ranunculaceae) is grown for its pungent seeds, which are used as a spice and in herbal medicine. The plant in question, belonging to the Ranunculaceae family, is an annual species cultivated primarily for its aromatic seeds. These seeds are highly valued for their culinary applications as a spice and their use in herbal medicine [3]. Black cumin seeds and their oil are prominent in Ayurveda and traditional Islamic medicine as therapeutic agents for treating several ailments, including chronic illnesses [4]. Thymoquinone (TQ), the most prevalent quinone compound, is a phytoconstituent found in black cumin. TQ possess valuable medicinal properties such as antimicrobial, anti-inflammatory, anti-oxidative, hypolipidemic, hypoglycemic, and bronchodilatory effects, as well as being used for the treatment of metabolic syndrome and auto-immune disorders [5]. Clinical evidence supports the seeds' antiparasitic, antibacterial, and antifungal activities. Additionally, several animal experiments have shown the ability of these seeds to suppress cancer growth [6]. Anti-inflammatory properties of NS and its secondary metabolites were reported in some inflammation-based models, including asthma, cancer, rheumatoid arthritis, and colitis [7,8]. NS has shown inconsistent results on oxidative stress and inflammation biomarkers in several clinical studies [9,10]. Notwithstanding the extensively documented anti-inflammatory effectiveness observed in the experimental model, the precise mechanisms underlying its anti-inflammatory effects in diverse chronic inflammatory diseases and its multi-targeting characteristics remain largely unexplored. Thus, this review explored NS and its secondary metabolites, a valuable source for the therapeutic development of chronic inflammatory diseases. This study will be a significant resource for clinicians and biologists seeking a pharmaceutical solution for inflammatory diseases.

## 2. The Methodology of the Literature Review

A comprehensive and systematic data search was used to conduct a literature survey. We have searched the data using multiple electronic databases, such as Science Direct (<http://www.sciencedirect.com/>, accessed on 2 July 2023), PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>, accessed on 28 July 2023), Web of Science (<https://apps.webofknowledge.com/>, accessed on 10 August 2023), Scopus (<http://www.scopus.com/>, accessed on 17 August 2023), and also search by Google Scholar, as well as various books and theses/dissertations. The keywords used to explore the literature for this review were "*Nigella sativa*", "Black cumin", "black seed", "kalonji", "Antioxidant"; "anti-inflammatory", "Immunomodulatory", "Anticancer activity", "Thymoquinone", "Antidiabetic activity", "cardiovascular disease", "Neurological disorder", "Obesity", "Asthma", and "COVID-19". Phrases such as the "pharmacological activity of *Nigella sativa* in different diseases" and a combination of phrases were used via electronic search engines. Figures have been drawn with the help of BioRender. We have listed all the relevant research papers from all the existing references and searched for suitable information for this review.

## 3. Global Distribution

People have used this plant for over a thousand years as a medicine. Evidence of the oldest cultivation of NS has been discovered by archaeologists, with dating indicating its presence as early as the 2nd century BCE [11]. *Nigella* is derived from the Latin word Niger, which means "black". The word "nigellus" denotes a shade of black or dark, ex-

PLICITLY referring to the color of the seed coat. The cultivation of black cumin is seen in several regions throughout Asia, Africa, Europe, and the Americas. NS is growing wild in Turkey, Iraq, Iran, Syria, and Africa [12]. The species is also grown commercially in India [13] and other parts of Southern Asia, Pakistan [14], Iran [15], Western Asia [16], Iraq [16], Israel [17], Jordan [18], Syria [19], Lebanon [20], Turkey [21], Yemen [21], Sudan [22], Northern Africa [22], Egypt [16], Tunisia [16], Ethiopia and Eastern Africa [23]. The primary nations engaged in the production of the commodity are India, Bangladesh, Sri Lanka, Pakistan, Afghanistan, Iraq, Iran, Syria, Ethiopia, and Turkey. Black cumin's natural average productivity has been reported to be 0.79 tons/ha. In 2018, the black cumin oil market was valued at over 15 million USD; substantial growth is anticipated by 2025 [24]. India cultivates this plant on a large scale due to its heavy consumption in medicine. Annual quantities of black cumin are estimated to be traded in India for more than 100 metric tons. According to Gashaw's (2020) findings, the average yield in Ethiopia was recorded at 0.64 tons per hectare, a significantly lower figure compared to other nations known for their high agricultural productivity [23]. In 2015, Ermias et al. said the low production was because the cultivars were not very productive [25]. In 2008, Hammo said that it was because the farmers were not using good agronomic practices [26].

### 3.1. Traditional Uses of *Nigella*

Evidence shows that it was cultivated, used in cooking, and even used as medicine in Mesopotamia from the late 3rd millennium BCE to the late 1st millennium BCE [27]. NS is described in Cuneiform tablets discovered at excavation sites in ancient Assyria (modern-day Turkey, Syria, Iraq, and Iran) as a divine herb that can be used to treat cases of "ghost possession" by fumigating an area with a mixture prepared from NS seed [27,28]. The significance of NS may be assessed based on the observable exportation of this plant from the Mediterranean region. The archaeological findings discovered in the Roman quarries of Mons Claudianus and Mons Porphyrites dating back to the 2nd century provide compelling evidence for the existence of a trade network involving the transportation of *Nigella* seeds from the Mediterranean region to other regions in Western Europe [29,30]. The production of mineralized NS seeds in Germany provides evidence to support the hypothesis of the historical trading of *Nigella* in this geographical area. Dioscorides, a Greek pharmacobotanist, mentions "the black seeds" of a plant called melanthion (NS) in his book "De Materia Medica", which was published between CE 40–90. He describes its use in foods like pickles and bread and as a treatment for headaches, skin problems, toothaches, leprosy, roundworms, sight imperfections, breathing ailments, urination difficulties, menstrual problems, etc. [31]. This wonder herb has been used in folkloric traditional medicine for thousands of years, long before the development of modern medicine. Unani, Tibb-e-Nabwi, Siddha, Ayurveda, Greek, Roman, Malay, and Jewish texts are some of the many ancient cultures whose written traditional medicinal texts mention this plant [32]. *Nigella* seeds, also known as black seed and black cumin, have been widely used as medicinal remedies throughout many Abrahamic civilizations. The black seed is widely acknowledged for its notable therapeutic attributes, being considered a panacea for all ailments except for mortality [33–35]. In tibb-e-nabawi or Prophetic medicine, NS is used expertly [34,35]. *Nigella* is referenced in the Bible on four occasions, including the New and Old Testaments [22].

*N. ciliaris* and *N. damascena* species of *Nigella* have been shown to provide various health benefits. Although *N. damascena* has been used since the Bronze Age in Central Europe, its ethnobotanical significance cannot be conclusively established. Its origins are still unknown; it has never been seen growing wild in Central Europe [36]. *N. damascena* seeds are a galactagogue in traditional Sicilian medicine [37]. In Serbian mediaeval medicine, this plant is also a helminthic agent to cure skin conditions like hematuria [38]. Italy and Tunisia traditionally use *N. damascena* for treating trachoma [39]. In addition to being used as an herbal cure, *N. damascena* is a condiment in several places [36], including Morocco [40]. *N. ciliaris* seeds are used in the traditional medicine of Palestine and Iran to


cure menstrual cycle-related issues, ease childbirth, and relieve stomach discomfort [41,42]. The dried blossoms of *N. arvensis* are used to make winter tea in the Turkish city of Meriç Town [43]. In Iran (Kerman), however, a mixture of *N. arvensis* seed flour and other seeds is administered to enhance male potency and increase memory and intelligence [43,44]. Both *Nigella* species' seeds are used for treating cancer in Palestine [45,46]. Formulation of black cumin essential oil nanoemulsions (BCO-NE) using different ratios of essential oil with canola and flax seed oils (ripening inhibitors) were formulated and stabilized with octenyl succinic anhydride (OSA) modified waxy maize starch for the antimicrobial use [47]. Pioglitazone is incorporated into a nanoemulsion formulation prepared with NSO to boost the action of Pioglitazone [48]. Numerous individuals use the oil to treat skin disorders like eczema, psoriasis, and blisters. Black seed oil combined with beeswax is also used as a moisturizer, anti-wrinkle agent, burn salve, and treatment for skin infections and joint discomfort. Various traditional uses of *Nigella* species are exhibited in Figure 1.



**Figure 1.** Various traditional uses of *Nigella* species.

### 3.2. Usefulness of NS in Religious and Medical Scripts


Religious texts have mentioned the names of medicinal plants, their preparation, and their significance [49,50]. The Prophetic Medicine and the Bible, two essential works from the Ancient and New Testaments, refer to NS (Isaiah 28:25:27 and Matthew 23:23). NS is mentioned more often than any other plant in the Bible. It is used for both birth control and cancer therapy [51]. According to Hippocrates, Dioscorides, and Pliny, NS is the medicinal “black cumin” mentioned in the Bible. It is also referred to as Melanthion and Gith [52]. Prophet Muhammed (Peace Be Upon Him), NS seeds may cure all ailments and diseases except death (Al-Bhukhaari, 5688). Ibn Sina, well-known in the West as Avicenna, and who wrote the renowned book “The Canon of Medicine,” advised about using NS. It increases the body’s vitality and aids in the body’s recovery from exhaustion and depression. Pedanius Dioscorides described utilizing NS seeds for culinary and medicinal uses, including treating eye disorders, toothaches, and leprosy, increasing urination, and repelling snakes [4]. Black seeds and honey syrup were a traditional medicine of the time of Nabi-e-Akram (Peace Be Upon Him), as attested to in the writings of Seerah. Reviewing the relationship between sickness treatment and the meals that the Prophet Muhammad (PBUH) advocated in light of contemporary superfoods [53,54]. Suhar Bakht identified NS, which he dubbed hab-i-Sajzi, or Sigzi grains. The health benefits of *Nigella sativa* were recommended by various scholars, as shown in Figure 2.

<p><b>Hippocrates</b> 460–370 BC</p>  <p>Vaginal, oral thrush and skin conditions of women and children.</p>	<p><b>Pharaoh Tutankhamen</b> 1341–1323 BC</p>  <p>Cerebral malaria and Epilepsy</p>	<p><b>Dioscorides</b> 40–90 AD</p>  <p>Nasal congestion, toothaches, cure headache, intestinal worms, and promote menstruation and milk production</p>	<p><b>Galen</b> 129–210 AD</p>  <p>Hepatic and digestive disorders, common cold, and stimulants in a variety of conditions</p>	<p><b>Al-Biruni</b> 973–1048 AD</p>  <p>Improve the energy and regain exhaustion</p>	<p><b>Ibn Sina</b> 980–1037 AD</p>  <p>Vaginal, oral thrush and skin conditions of women and children.</p>
---	---	---	--	---	---

**Figure 2.** The health benefits of *Nigella sativa* recommended by various scholars.

#### 4. *Nigella sativa*, the Plant, and Its Phytoconstituents

In recent years, significant advancements have been achieved in phytochemistry, and health supplements have gained prominence. The medicinal plant is called a chemical manufacturing industry, since it produces a variety of bioactive molecules such as alkaloids, saponins, oleoresins, resins, glycosides, sesquiterpene lactones, and oils [55]. NS's most abundant chemical components are thymoquinone,  $\alpha$ -phellandrene, thymol, proteins, oleic acid, and carbohydrates [7,56]. Previous research has isolated and characterized the primary components of black seeds, including palmitic acid, oleic acid, linoleic acid, and trans-anethole [57]. A study by Kumar et al. found Quiones (thymohydroquinone, thymoquinone, dithymoquinone) and phenolics [58]. Black seed oil was analyzed by Harzallah et al. and yielded 48 unique chemicals, the majority of which were thymoquinone [59]. According to another research, NS seeds contained various chemicals, most of which were monoterpene hydrocarbons. The constituents of NS seed are 0.4–2.5% essential oil, saponin, alkaloids, and 36–38% fixed oils [60]. Unlike most oils, fixed oil contains the unusual fatty acids C20:2arachidic and eicosadienoic [61]. Burits and Bucar et al. analyzed the essential oil using GC-MS. The major components were characterized as thymoquinone (27.8–57.0%), carvacrol (5.8–11.6%),  $p$ -cymene (7.1–15.5%), trans-anethole (0.25–2.3%), longifoline (1.0–8.0%), and 4-terpineol (2.0–6.6%). Dithymoquinone is easily formed when thymoquinone dimerizes [62]. The chemical structures of some main constituents of *Nigella sativa* seeds are shown in Figure 3.



**Figure 3.** Chemical structures of some main constituents of *Nigella sativa* seeds.

## 5. Pharmacological Activities of *Nigella sativa*

Numerous pharmacological effects have been observed for the most widely used traditional medicinal herb, *Nigella sativa*. Thymoquinone, one of the bioactive compounds found in NS, can cause oxidative stress-induced cell apoptosis, enhance membrane permeability, obstruct efflux pumps, and exert potent biocidal effects.

### 5.1. Antioxidant and Anti-Inflammatory

Inflammatory responses are biological processes that protect us from harmful stimuli by coordinating the production of pro- and anti-inflammatory endogenous mediators [63]. NS is a free radical scavenger and improves the action of antioxidant enzymes (glutathione peroxidase, catalase, and glutathione-S-transferase). Thymoquinone's anti-inflammatory effects were primarily seen in models of inflammation caused by rheumatoid arthritis, colitis, cancer, and asthma [7]. It has been shown to have an anticancer effect via modulating several molecular targets, including p53, p73, STAT3, PTEN, PPAR-g, caspase activation, and reactive oxygen species (ROS) [64]. *Nigella sativa* seed essential oil was tested for its potential antioxidant properties. An examination was conducted in this study using two TLC screening methods. The results of the study have shown that thymoquinone and the components trans-anethole, carvacrol, and 4-terpineol have antioxidant potential [64].

Regarding managing hyperglycemia and boosting beta cell production in the pancreas, NS is superior to other plant species, thanks to its potent antioxidant and antidiabetic characteristics [65]. Several human clinical studies have produced conflicting findings on the impact of NS on oxidative stress and inflammation indicators. Five different methanolic fractions on guinea pigs were investigated to identify the main constituents of the methanolic extract of NS. All the methanolic fractions had significant relaxant effects, and the 20% frac-

tions from NS were more than that of theophylline at the used concentrations [66]. *Nigella sativa* seed oil is widely used in the Mediterranean region for its anti-inflammatory properties [67]. Both NS oil and thymoquinone are effective anti-inflammatory agents, reducing the production of inflammatory mediators, including prostaglandins and leukotrienes, in animal models of diseases such as colitis, encephalomyelitis, oedema, peritonitis, and arthritis [68]. At a 4 mL/kg/day dose, NS oil suppressed NO and IL-4 production in rats when given orally for 31 days [69]. Clinical studies have also shown NS's anti-inflammatory properties, such as when the oil was administered to older people with osteoarthritis [70]. NS, for instance, may be helpful as a topical therapy for psoriasis. A little research has shown the topical benefits of NS oil. NS, for example, may be beneficial as a topical therapy for psoriasis [71]. Indomethacin and nanoparticles derived from NS essential oil have been demonstrated to have anti-inflammatory effects [72]. A study examined the anti-inflammatory and antioxidant activities of the oil extracted from seeds of NS and its biological activity.

### 5.2. Immunomodulatory Effects of *Nigella sativa*


Modifying the immune response by controlling communication between its many parts—for example, between neutrophils and macrophages or T and B cells—is known as immunomodulation. Immunomodulators can stimulate or repress the immune system, aiding immunological function [73]. The research on the immunomodulatory properties of NS seed extracts, fixed oil, and essential oils that have been published so far is reviewed [74]. It was investigated in vitro how NS seeds and their soluble fractions affected the reactivity of lymphocytes to various mitogens and the phagocytic activity of polymorphonuclear leukocytes. It was observed that NS stimulates the lymphocyte response to combined allogeneic cells. When cultured with pooled allogeneic cells or without any additional stimulator, NS increased the production of interleukin-3 by human lymphocytes. Interleukin-1 was found to be elevated in response to NS, indicating an influence on macrophages. However, when *Staphylococcus aureus* was utilized, no impact of NS or its fractions was seen on bacterial phagocytosis or killing, suggesting that the reduction in chemiluminescence activity in the presence of NS is unrelated to the bactericidal activity [75,76]. An increasing body of experimental research indicates that NS and its active components have powerful and positive immunomodulatory effects. NS has been demonstrated to include elements that stimulate T cell-mediated immune responses and inhibit B cell-mediated immunological responses [77,78]. More research is needed to confirm previous findings and uncover novel immunotherapeutic properties of this promising medicinal herb, NS, because few studies have focused on examining NS's potential immunomodulatory and immunopharmacological effects and its active ingredients.

### 5.3. Anticancer Activity

The widespread prevalence of cancer makes it a top global health concern [79,80]. We must simultaneously address many global health issues to combat this threat. High death and morbidity rates demonstrate the ineffectiveness of clinical cancer rehabilitation, which includes immunosuppression, chemotherapy, radiation, and surgery. It has increased the need to develop new, more reliable methods of cancer therapy and prevention [81–83]. Herbal therapeutics are thus reborn through dietary supplements and botanical preparations. Unique chemical compounds with therapeutic potential are abundant in these medicinal plants [84–87]. Secondary metabolites are the bioactive substances found in plants and are the building blocks of phytochemicals [88–90].

Interestingly, around 60% of anticancer medications have a natural origin [91]. We have compiled a summary of the many anticancer actions linked to NS in this section. Numerous bioactive compounds have been identified in NS seeds. The seeds comprise fixed and essential oils, alkaloids, saponin, and proteins [92,93]. NS's critical bioactive component, thymoquinone (TQ), is responsible for the plant's positive anticancer effect. In-vitro and in-vivo studies have demonstrated that TQ has decisive anticancer and an-

tiproliferative activities against liver, blood, respiratory tract, kidney, colon, and prostate cancers. Combination cancer treatment with NS extract or TQ has been shown to reduce the toxicity of traditional cancer medications, while improving the quality of life for people with advanced cancer [94]. The anticancer activity of (R)-limonene was shown to be mediated by the process of apoptosis and the modification of polyamine metabolism. The compound limonene can trigger apoptosis in LS174T colon cancer cells via a mechanism that involves the mitochondria [95]. Researchers discovered that  $\alpha$ -hederin caused a dose- and time-dependent rise in the death of murine leukaemia P388 cells.  $\alpha$ -hederin has been shown to exhibit strong antitumor activity in vivo [96]. The efficacy of derivatives derived from TQ-bearing terpene-terminated 6-alkyl residues was evaluated in 518A2 melanoma and HL-60 cells. They discovered that the derivatives cause a slight rise in reactive oxygen species, a drop in mitochondrial membrane potential, and apoptosis linked to DNA laddering [97]. It was discovered that NS extracts, both aqueous and alcohol-based, were successful in vitro in deactivating MCF-7 breast cancer cells [98]. TQ has anti-neoplastic properties and promotes apoptosis in the HCT116 colon cancer cell line [99]. The study conducted by Salim et al. demonstrates the ability of the volatile oil of NS to inhibit colon carcinogenesis in rats at the post-initiation stage, without any observable adverse effects [100]. TQ was potent against the SW-626 colon cancer cells, and the results were similar to 5-fluorouracil in action on HT-29 cells [101]. Chehl et al. also suggested TQ as a new way to stop pro-inflammatory pathways. This idea is promising because it combines ways to control inflammation and help cells die [102]. The anticancer activity of TQ is attributed to potent antioxidant properties in normal cells, and prevents the formation of lipid peroxidation and radicals. TQ acts as a prooxidant, increasing ROS production and causing cancer cells to die after oxidative damage. TQ causes cancer cells to undergo apoptosis by upregulating the transcription factor p53, which promotes apoptosis. Upregulation of the proapoptotic p53 transcription factor is how TQ causes cancer cells to apoptosis. TQ is a cytoprotective molecule that mitigates the harmful effects of chemotherapy on healthy cells without interfering with the therapeutic effects of the drugs themselves in the fight against cancer. It stops cancer cells from dividing and halts the process of angiogenesis [94]. Figure 4. exhibits the possible anticancer mechanism of action of thymoquinone (TQ).




**Figure 4.** Possible anticancer mechanism of action of thymoquinone (TQ). “+” Means increase and “-” means decrease.

#### 5.4. Antidiabetic Activity

Diabetes is a chronic disease caused by the pancreas' inability to produce or properly use insulin. Patients with diabetes mellitus often turn to herbal remedies for relief. Dyslipidemia, elevated oxidative stress, and changes in the body's antioxidant defense system may all be associated with diabetic complications [103]. Worldwide, 451 million people between the ages of 18 and 99 years have diabetes. By 2045, their numbers were predicted to rise to 693 million. Nearly half of all patients with diabetes (49.5%) are thought to remain undiagnosed. In addition, it was predicted that over 21.3 million live births to women were impacted by some hyperglycemia in pregnancy, and it was expected that 374 million individuals had impaired glucose tolerance (IGT). The prevalence of diabetes-related complications was estimated to range from 20 to 90.5% across several studies [104]. Although there is currently no cure for diabetes mellitus, it may be controlled with medications like insulin and dietary changes. Alternative treatment might come from using medicinal herbs [105].

The therapeutic promise is associated with various medicinal plants and their isolated constituents. Diagnosing the antidiabetic characteristics of food items supplemented with medicinal plants often involves measuring the inhibition of  $\alpha$ -glucosidase and  $\alpha$ -amylase enzymes. The enzyme  $\alpha$ -amylase breaks down carbs into simpler disaccharides, while the enzyme  $\alpha$ -glucosidase converts the simpler disaccharides into the more easily absorbed glucose [106,107]. This disease can be treated safely and effectively with natural compounds that inhibit these enzymes [108,109]. Diabetes-induced endothelial dysfunction is protected by thymoquinone. Endothelial dysfunction caused by diabetes is mitigated by thymoquinone. Numerous mechanisms are employed to achieve this, including the decrease in inflammatory and apoptotic markers, enhancement of hyperlipidemia, hyperglycemia, and antioxidant function, inhibition of platelet aggregation, and regulation of gene expression related to VCAM-1, eNOS, and LOX-1, which is implicated in endothelial dysfunction. TQ also inhibits the expression and secretion of specific cytokines, including interleukin-1 $\beta$ , MCP-1, NF- $\kappa$ B, TNF- $\alpha$ , and Cox-2, resulting in an anti-inflammatory effect [110]. Patients with type 2 diabetes were given NS seeds as an adjunct treatment to their anti-diabetes drugs [111]. TQ is one of the principal bioactive chemicals shown to have a defensive effect against diabetes, and it is mainly responsible for the therapeutic actions of NS [112]. Previous research has shown that TQ significantly lowers fasting blood glucose (FBG) and significantly boost rats' insulin levels [113]. The results of the scrutiny on the effects of NS extract on diabetes demonstrate that NS extract decreases blood glucose and lipid levels in diabetes. The present portion of the reviews indicates that NS and TQ protect against endothelial dysfunction brought on by diabetes, thanks to their antidiabetic, antioxidant, anti-thrombotic, and gene-regulatory activities. Figure 5 exhibits the various complications associated with diabetes.



**Figure 5.** Various complications associated with diabetes.


### 5.5. Cardiovascular Disease (CVD)

An acute myocardial infarction is consistently ranked as one of the leading causes of death worldwide. Clinical investigators investigated the possible impact of delivering cells to the chemically wounded heart. C-reactive proteins (CRP) are produced in the blood due to inflammation, and their concentration increases as inflammation worsens. Advanced coronary artery inflammation is caused by a pocket of fatty, soft plaque that accumulates and seeps into the artery channel. Rehabilitative methods for the heart include antioxidants, plant life, and physical activity [1]. More people in middle-income nations die from cardiovascular disease than in high-income countries, says the World Health Organization. CVDs are a group of disorders in the heart and blood vessels responsible for the death of approximately 23.6 million people worldwide [114]. People with risk factors like diabetes, high cholesterol, or high blood pressure need more intensive medical and psychological support [115].

One of the most crucial protective factors against CVDs may be eating a diet low in salt, free sugar, and fat, and high in natural plant products [116]. One of NS's active components, TQ, has been shown to have several biological benefits. Anticancer, antidiabetic, anti-inflammatory, hypolipidemic, and other therapeutic uses of TQ have been established. Flavonoid-rich plants have been utilized for centuries to treat various conditions [117,118]. Due to their antioxidant, anti-inflammatory, and vasodilatory properties, flavonoids are gaining much ground in contemporary pharmacology as a viable therapy for CVDs [119]. TQ contains several bioactive substances [120].

TQ protects against coronary artery diseases, diabetes, hypertension, inflammation, apoptosis, and oxidative stress. TQ's anti-inflammatory and antioxidant activities may cause its clinical effect against various diseases [121]. TQ's antioxidant impact is linked to its scavenging ability against reactive oxygen species (ROS), whereas its anti-inflammatory effect is linked to its inhibitory effects on 5-lipoxygenase and cyclooxygenase [122]. TQ also forms glutathione-dihydro-TQ when combined with glutathione (GSH), NADPH, and NADH; this compound is effective against free radicals [123]. It has been noted that TQ has protective properties for treating and inhibiting CVDs [124]. This section demonstrates how TQ may treat cardiovascular disorders by reducing oxidative and inflammatory reactions. TQ has anti-inflammatory and antioxidant properties, which it uses to combat the many disorders that arise from an imbalance of inflammation and oxidative stress. Although TQ has been found to have cardioprotective benefits in vivo and in vitro settings, the same

cannot be said for clinical studies, and more safety evaluations are required to identify the harmful qualities of TQ in people. Additionally, further research is needed to verify its traditional usage as a therapy for cardiovascular disorders. Different mechanisms of actions of *Nigella sativa* and its phytoconstituents for antioxidant, anti-inflammatory, and antihyperlipidemic effects are shown in Figure 6.



**Figure 6.** Different mechanisms of *Nigella sativa* and its phytoconstituents for antioxidant, anti-inflammatory, and antihyperlipidemic effects. The blue arrows indicate decreased effects and red arrows indicate increased effects following NS administration.

### 5.6. Neurological Disorder

One of the worst outcomes of becoming older is neurodegenerative illnesses, which are caused by damage to the nervous system and abnormal biochemical processes in the body. Neuroprotective and neurotrophic effects are at the forefront of current neuroscience and improve brain health. The elderly are particularly vulnerable to neurodegenerative diseases. Neurological disorders are depression, insomnia, and neurodegenerative diseases; common pathological conditions are neurogenesis impairment, neurotrophic factor deficiency, and oxidative disorder stress. Damage to neurons is exacerbated when microglia and astrocytes are activated in response to oxidative stress, increasing the production of pro-inflammatory mediators. Neuronal injury and degeneration result from producing inflammatory cytokines, creating amyloid plaques and neurofibrillary tangles (NFTs) [1]. Many neurodegenerative diseases have no known cure, and the commercial

medications available to treat them all have significant drawbacks. Scientists are thus looking for effective medicines with little adverse effects. Researchers are interested in various phytochemicals because of their potential therapeutic benefits and low risk of negative consequences.

There are many different types of herb plants, and NS is only one of them. Many illnesses, including inflammation, oxidative stress, bacterial/fungal infection, and neurological disorders, have been researched concerning the chemical components of plants. In this section of the review article, we have examined the role of NS and its secondary metabolites against neurodegenerative diseases. Ayurveda also recommends the extensive use of the black seeds. It aids in the healing of a wide variety of conditions, including those manifesting in the kidneys, the digestive system, the liver, the eyes, the heart, and the nervous system [125].

Numerous investigators have elucidated the actions and impacts of NS on the central nervous system. Alzheimer's disease (AD) and Parkinson's disease (PD) are two examples of neurodegenerative illnesses; NS is known to protect against neurotoxicity and cytotoxicity in such cases [126–128]. Amyloid  $\beta$  protein ( $A\beta$ ) is the main component of neuritic plaques in Alzheimer's disease (AD), and its accumulation has been considered the molecular driver of Alzheimer's pathogenesis and progression.  $A\beta$  has been the prime target for the development of AD therapy [129]. Additionally, it has been shown that NS seed extracts, both aqueous and methanolic, have sedative solid and depressive effects on the central nervous system; in addition to having analgesic properties, diseases like Alzheimer's cause gradual brain shrinkage and the buildup of senile plaques in the cortex. Amyloid-beta ( $A\beta$ ) is a peptide with a molecular weight of 4.2 kD, and there is pathological evidence that it aggregates in the central nervous system [130]. Several studies have studied and supported the concept of NS's anti-Alzheimer's action.

Recent evidence from Elibol et al. demonstrates that micro-osmotic pumps carrying  $A\beta_{1-42}$  may be successfully cannulated into the hippocampus area of adult female rats, where the impact of TQ can then be tested. After eliminating A plaques and restoring neuron viability, the researchers found that TQ (10 and 20 mg/kg) was effective against AD and led to improved memory [131]. TQ was found to be effective against A deposition and its neurotoxicity in human iPSC-derived cholinergic neurons and LPS/IFN-gamma-activated BV2 microglia cells by increasing antioxidant levels and decreasing synaptic plasticity and pro-inflammatory mediators by modulating NF-kappa B (NF-kb)-mediated signaling molecules [132,133]. When injected intraperitoneally at doses of 5 and 10 mg/kg for 4 weeks, TQ was similarly shown to significantly restore memory and learning functioning in male Wistar rats [134]. It has also been shown that NS seeds' aqueous and methanolic extracts have a potent central nervous system depressant and analgesic effect [135]. The antioxidant and free radical scavenging characteristics of NS, which have been shown to improve memory, are likely attributable to the presence of one or more of its components [136]. It has been demonstrated that NS oil prevents lipid peroxidation in the hippocampus of rats subjected to ischemia-reperfusion damage [137]. Studies have shown that a component of NS is neuroprotective, and this effect has been demonstrated in several disease states, including type 2 diabetes. In most cases of neural dysfunction, an active insulin signaling cascade is neuroprotective. The oxidative stress, pro-inflammatory mediators, and amyloidogenic pathway are all modulated by NSO therapy in a model of Alzheimer's disease in type 2 diabetic rats. Intriguingly, scientists have also examined the brain's miRNA pool following NSO therapy, revealing a return to pre-AD levels [138].

### 5.7. Obesity

Several factors have contributed to the alarming rise of obesity in recent decades [139]. The World Obesity Atlas 2022, published by the World Obesity Federation, predicts that one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. The findings highlight that countries will not only miss the 2025 WHO target to halt the rise in obesity at 2010 levels, but that the number of people with obesity is on course

to double across the globe [140]. Obesity has been linked to an increased risk of many chronic illnesses, including CVDs, atherosclerosis, type 2 diabetes, various forms of cancer, and non-alcoholic fatty liver disease [141]. Reducing caloric intake and increasing exercise are two of the cornerstones of obesity therapy, along with the use of anti-obesity drugs. However, synthetic anti-obesity drugs have adverse side effects, and their effectiveness frequently wanes with continued usage [142]. The public and scientific community have recently shown much interest in plant-based nutrition and medicinal plants as potential alternatives to conventional medicine. Compared to synthetic medications, medicinal plants are easier to get, cheaper, and have fewer adverse side effects [143]. Some medicinal plants have shown promise for treating obesity and related health issues [143,144]. NS, also known as black seed, is one of these herbs [111,145–147].

There is ongoing debate about whether NS is effective as an adjunct treatment for weight loss. TQ, which comprises up to 30–48% of NS oil, has been linked to medicinal benefits, including its ability to reduce body fat, which was discovered in recent studies. The pharmacological effects of NS may also be due to other compounds found in the plant, such as thymohydroquinone, thymol, thymoquinone, nigellone and its derivatives; nigellone and its derivatives; nigellone and its derivatives; fatty acids; and flavonoids [148]. The consumption of NS was shown to reduce food intake and enhance energy expenditure in animal models [149–151]. In addition, the plant showed no adverse severe or toxicological effects in either human or animal studies [147,149,152,153]. While NS has been shown to help with weight control in certain studies, others have shown little to no benefit [9,147,154–158]. Therefore, the evidence for suggesting NS as a weight-loss supplement is still lacking. Various clinical trials showed that the supplementation with NS exerted moderate effects as a complementary therapy for reducing body weight. No severe side effects were also reported following NS supplementation. Figure 7 shows the chronic problems associated with obesity.




Figure 7. Chronic problems associated with obesity.

### 5.8. The Influence of NS on Asthma Control

Inflammatory mediators, chronic inflammatory reactions, and oxidative stress play a central role in the pathogenesis of many lung disorders, such as tracheitis, chronic obstructive pulmonary diseases, and asthma [159]. The prevalence of asthma ranges from 1% to 18% worldwide, making it a severe public health concern [160,161]. The symptoms result from a persistent inflammatory process that is mediated and coordinated by the byproducts of specific immune cells [162,163]. However, no effective asthma preventive measures or cures have been discovered, and current treatment focuses on achieving and maintaining clinical control. These strategies may not prevent asthma-related chronic inflammation and remodeling [164,165].

Herbal remedies for asthma in humans and animals have come a long way in recent years [166]. For over 2000 years, NS has been used to treat various illnesses. Research on humans and animals has suggested that NS may have anti-asthmatic properties [93,167,168]. NS has healing and protective properties, such as bronchodilation, reducing inflammation, and protecting against allergies. It also works well at changing the immune system to treat many lung diseases [169–171]. It can inhibit histamine receptors, has anti-cholinergic properties, and relaxes various smooth muscle preparations [172–174]. In earlier research, NS has been shown to have immunomodulatory, anti-inflammatory, and antioxidant properties [68]. NS has been studied in limited clinical trials for its potential in alleviating asthma symptoms, with results showing substantial improvements in subjective well-being and pulmonary function [175–177]. Supplementation with NS for asthmatic patients is not yet supported by enough data to be used routinely in clinical practice. NS supplementation for these individuals has been the subject of numerous recent research, with mixed outcomes [178]. There needs to be more in vivo research showing the effects of NS oil on animals and people [179]. The authors investigated the effects of NS oil in an experimental model of allergic airway inflammation in rats. Oil was injected intraperitoneally before exposing rats to ovalbumin (OVA). The authors examined spleen T cell proliferation and evaluated total IgG1, IgE, and OVA-specific IgG1 blood levels. In addition, they analyzed the expression of genes encoding various cytokines, such as IL-4, IL-5, IL-6, and transforming growth factor-1 (TGF-1). NS oil inhibited inflammatory cell infiltration and pathological lung lesion development, demonstrating its ability to dampen Th2-type responses in rats. NS oil treatment also inhibited T-cell proliferation in the spleen [179]. Balaha and his colleagues studied how giving NS oil to a mouse model of allergic asthma could reduce inflammation and change the immune system. Oral administration of 4 mL/kg/day NS oil dramatically reduced airway responsiveness in OVA-sensitized mice [168].


Numerous clinical research indicated that NS extract has bronchodilator, preventative, and curative therapeutic effects on individuals with chronic asthma, leading to a substantial reduction in blood biomarkers of asthma and an improvement in asthmatic symptoms. It also resulted in a 5–75% improvement in peak expiratory flow. The inhibition of histamine release and practical anti-inflammatory effects on mast cells after treatment with NS formulations resulted in lower fractional exhaled NO and serum IgE levels, respectively [170,171,180]. There is a balance between Th1 and Th2 cytokines, thanks to the activation of immune cells and the initiation of the antigen presentation system by black cumin seed or its active compounds. The bioactive compounds in black cumin seeds make it easier for LC3II to turn into LC3III, which is a sign that autophagy is starting to work. Black cumin improves anti-histamine, anti-inflammatory-GPx, and SOD-responses, while reducing inflammation and oxidative stress [181]. These results suggest that oral supplementation with NS may be helpful in the treatment of bronchial asthma.

### 5.9. *Nigella sativa* for the Treatment of COVID-19

The first identification of Coronavirus disease-2019 (COVID-19) occurred in China in December 2019. This illness's causative agent has been Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). SARS-CoV-2 has since disseminated globally, precipitating a substantial epidemic and posing significant obstacles to global healthcare systems [182–184].

The majority of individuals inflicted with COVID-19 exhibit either no symptoms or a mild illness that can typically be controlled with the administration of antipyretics, analgesics, hydration, and the application of constitutional symptoms; clinical deterioration is closely monitored [185]. In light of the ongoing epidemic, the quest for a viable therapeutic intervention has emerged as a paramount focus within scientific medical investigation [186].

There are not currently many pharmacotherapeutic medications available that work against COVID-19. Hence, the potential use of complementary herbal medicines, which possess diverse biologically active compounds, is being explored as a therapeutic approach for combating coronavirus infection [81,160,166]. These therapeutic interventions are often used to treat respiratory disorders, and reports have shown their effectiveness in alleviating influenza-related symptoms [187]. *Nigella sativa* has been recognized as a promising phytomedicine owing to its diverse pharmacological properties, including antiviral, anti-inflammatory, and immunomodulatory actions [188,189]. NS is a well-known cooking spice that has significant health benefits and an extensive history [7,187]. Numerous bioactive constituents have been discovered inside NS, among which thymoquinone is a prominent component [7]. Thymoquinone safety profile has been the subject of multiple clinical studies, one of which involved asthmatic patients and was completed by us [190]. Many preclinical and clinical investigations have provided evidence of NS's antiviral properties against various viruses [191–197]. Research conducted in vitro demonstrated a reduction in the viral load of the coronavirus when exposed to NS [197]. Certain compounds derived from NS have shown promising inhibitory effects on the propagation of coronaviruses in computational models [198]. Several chemical compounds present in NS, including  $\alpha$ -herein, nigellidine, hederagenin, thymoquinone, and thymohydroquinone, have shown promise as active molecules that might suppress the coronavirus [198]. There is a need to do more preclinical studies to establish that NS might be fighting against coronavirus. A clinical study of NS in patients with COVID-19 is recommended to investigate its clinical efficacy if preclinical research provides positive results. Figure 8 exhibits the different mechanisms of action of *Nigella sativa* and its secondary metabolites for COVID-19.



**Figure 8.** Different mechanisms of action of *Nigella sativa* and its secondary metabolites for COVID-19. NS seeds and its active constituents activate immune cells, make balance between Th1 and Th2 cytokines and initiate antigen presentation system, decreases inflammation, increases anti-inflammation and antihistamine responses. Black cumin bioactive compounds increase autophagy activation by the conversion of LC3II to LC3III, improving comorbidities situation in SARS-CoV-2-infected patients and help in decreasing oxidative stress.

## 6. Clinical Trials

Clinical trials are studies that evaluate the effects of treatment on humans, whether pharmaceutical, behavioral, or surgical. Clinical trials are the gold standard for testing the efficacy and safety of potential new treatments and preventative measures in humans. New illness detection, diagnosis, and treatment methods are tested in clinical trials. Randomized controlled trials (RCT) are a kind of scientific experiment that aim to reduce bias when testing new interventions. Trial participants are randomly allocated either to the group receiving the treatment under investigation or to a control group receiving standard treatment (or a placebo) [199]. A clinical study was conducted to examine the effects of NS oil on the lipid profile, fasting blood glucose (FBG), and systemic inflammation in patients with (T2DM). Fifty type 2 diabetes patients were used in this randomized, double-blind clinical investigation. Patients were randomized to receive either an oil extracted from NS or a placebo. Results of the clinical study have shown that patients with T2DM who take an NS oil supplement see improvements in their lipid profiles and glycemia, as well as decreases in their C-reactive protein levels and lipid peroxidation [200]. Another trial was conducted to identify the possible blood glucose-lowering effects of the black seed oil on healthy subjects. Neither group had severe adverse effects on their livers, kidneys, or intestines. Giving 5 mL of black seed oil to healthy people every day for two months improved their glycemic profile without causing other problems [201]. NS and its secondary metabolites are used as antioxidants and anti-inflammatories in medical sciences. An examination was conducted to determine the effects of different fasting blood sugar levels and lipid profiles in nonalcoholic fatty liver disease (NAFLD) patients via a clinical study. Results showed that NS seed oil supplementation led to lower lipid profiles in the FBS [202].

Razmpoosh et al. conducted a clinical trial to determine the effect of NS oil supplements on CVD risk factors. Obese and overweight healthy women were randomized to receive NS oil (2000 mg/day) and placebo. This intervention period lasted eight weeks and was separated by a 4-week washout period. Overweight and obese women were randomized to receive 2000 mg/day of NS oil and placebo for eight weeks and separated for a 4-week washout period. The overall reductions in CVD risk factors demonstrated the advantageous effects of NS supplements in preventing potential cardiovascular diseases in adults who are obese [203]. NS seed oil was studied to see whether it could be used as a supplemental therapy for hypertension, glycemic control, and lipid metabolism, and if it was safe to do so. Patients with hypertension were randomly assigned to either the intervention ( $n = 26$ ) or placebo ( $n = 29$ ) groups, where they were given 2.5 mL of oil extracted from NS seeds twice daily for 8 weeks or sunflower oil. Supplementing with NS seed oil showed further antihypertensive benefits in hypertensive patients, with no adverse events recorded in the kidneys, the liver, or by the patients themselves, and positive effects on glucose control and lipid metabolism [204]. The risk factors for cardiovascular disorders are strongly associated with NAFLD. The study aimed to assess how supplementing with black seed affected the risk factors for cardiovascular diseases in NAFLD patients. Fifty people were included in this placebo-controlled, randomized clinical study of NAFLD treatment. For 12 weeks, participants were given either 2 g of NS or a placebo and advice on improving their lifestyle. The results show that patients with NAFLD benefit more from a combination of lifestyle changes and daily ingestion of 2 g NS than from lifestyle changes alone [205].

To find out the efficacy of NS in central obese men on waist circumference, body weight, blood sugar, lipid, adiponectin, hs-CRP Test (C-Reactive Protein High-Sensitivity), uric acid, and side effects in the treatment group compared to control. Participants aged 30 to 45 are randomly assigned to either a treatment or a control group and monitored weekly for three months. Results have shown that both body mass index and waist size decreased significantly, and that there was no significant effect on systolic and diastolic blood pressure. The therapy group showed no signs of adverse effects [205]. Dietary changes can effectively manage and prevent hypertension (HT), a disease associated with lifestyle choices. A double-blind, randomized, placebo-controlled study was conducted to

assess the effectiveness of oral NS seed extract supplementation as a treatment for patients with mild HT. Randomization assigned participants to receive either a placebo or 100 or 200 mg of NS extract twice daily. After 8 weeks, the systolic blood pressure (SBP) levels in both case groups were much lower than at the beginning of the study. The two case groups' SBP decrease was statistically significant compared to the placebo group. The findings indicate that moderate HT patients who take NS seed extract daily for 2 months may see a reduction in blood pressure [206].

Kalonji seed in capsules was examined for its impact on serum lipid levels, blood pressure, body weight, and blood sugar in adults. Sixty-four patients were assigned to the treatment group, while fifty-nine were assigned to the control group. Nearly all variables showed a positive effect from powdered Kalonji seed in capsule form. However, the small sample size prevented the results from being statistically significant [207]. Randomized and single-blind research examined how NS affects healthy senior participants' memory, attention, and cognition. NS's safety profile was also evaluated during the study's nine weeks. Forty senior citizens were enlisted and split evenly into groups (A and B), each with 20 participants. Group A was given 500 mg of NS in capsule form twice daily for nine weeks, whereas Group B was given a placebo instead of NS. The results of this research support the use of NS for improving learning, recall, and reasoning. Therefore, whether NS could be considered as a potential food supplement for preventing or slowing the progression of Alzheimer's disease needs further investigation. Before using NS daily, large-scale cohort studies with Alzheimer's patients are recommended, as are phytochemical studies for novel NS drugs for cognitive disorders [208].

People who are overweight or obese usually have higher risk factors for CVDs. As a result, a therapeutic approach aimed at controlling metabolic profile and body weight may effectively prevent CVDs. In a double-blind, randomized, controlled clinical trial, 90 obese women investigated the effects of NS oil and a low-calorie diet on obese women's cardiometabolic risk factors. All of the women in the study ranged in age from 25 to 50, and their body mass index (BMI) was between 30 and 35 kg/m<sup>2</sup>. For eight weeks, they were randomized to either a placebo or a low-calorie diet supplemented with 3 g (1 g before each meal) of NS oil daily. A total of 84 women participated in the study (43 in the intervention group and 41 in the placebo group). The fundamental features of the two groups were comparable. Both groups altered their diets after the intervention compared to before it, although the changes were not statistically different. More research is required to determine whether or not NS is effective as an adjunct treatment for obesity [209]. 50 volunteer obese women aged 25–50 years with 30–35 kg/m<sup>2</sup> were recruited in a double-blind, placebo-controlled randomized clinical trial. When used with a calorie-restricted diet, NS oil led to more significant weight loss in the NS group than in the placebo group. Compared to the placebo group, those using NS oil lost more weight while on a low-calorie diet. Weight loss and elevated superoxidase dismutase (SOD) levels occurred simultaneously in obese individuals who used NS oil in conjunction with a reduced-calorie diet [210].

Khonche et al. conducted a randomized, double-blind parallel control study to treat patients with NAFLD. Every twelve hours, sixty patients got 2.5 mL of fully standardized NS seed oil, and the other sixty patients received a placebo for three months. Outcomes have shown that NS seed oil seems safe and improves liver steatosis, LDL-C, HDL-C, and injury in NAFLD patients [211]. The NS intervention's effects on weight, height, waist circumference, and other body measurements, as well as food consumption and satiety, were studied in a randomized, double-blind, crossover clinical study. Forty-five healthy women who were overweight or obese were randomized into two groups—intervention and placebo—the research was carried out throughout two 8-week intervention periods, with a 4-week washout period. Dietary consumption and anthropometric parameters were also assessed. The good effects of NS supplements in treating obesity are shown by overall improvements in body composition and anthropometric parameters and a significant decrease in appetite [212]. Table 1 shows the pharmacological effects of *Nigella sativa*.

**Table 1.** Summary of clinical trials showing the pharmacological effect of *Nigella sativa*.

Participants	Interventions	Comparisons	Outcomes	Study Design	References
Fifty type 2 diabetes patients	Two capsules of 1000 mg <i>N. sativa</i> oil were given daily to the intervention group for eight weeks.	Randomly assigned to intervention and placebo	NS oil supplements see improvements in their lipid profiles and glycemia.	RCT	[200]
Seventy healthy subjects	2.5 mL Black seed oil, two times a day.	NS oil vs. placebo (mineral oil)	Significant decrease in HbA1c levels and fasting blood glucose.	RCT	[201]
Forty-four patients with NAFLD	Once a day, 1 g of NS oil orally for 8 weeks.	NS oil vs. placebo (paraffin oil)	Supplementing with NS seed oil improved lipid profiles and reduced FBS.	RCT	[202]
Thirty-nine patients with obese and overweight healthy women	2000 mg/day of NS oil for eight weeks	NS oil vs. placebo	Reductions in CVD risk factors	RCT	[203]
Fifty-five with hypertension	2.5 mL/day of NS oil for eight weeks	NS oil vs. placebo	Positive effects on glucose control and lipid metabolism	RCT	[204]
Fifty patients with NAFLD.	2 g NS plus lifestyle modification	NS or placebo	Improve insulin resistance	RCT	[205]
One hundred and twenty-three	Kalonji seed in capsules form	Kalonji seed vs. placebo	Positive effects on FBS, serum lipids.	RA/DB/parallel	[207]
90 obese women	3 g (1 g before each meal) of NS oil daily	NS oil vs. placebo	Weight and waist circumference decreased significantly.	RA/DB/parallel	[209]
50 obese women	a low-calorie diet with 3 g/day NS oil	NS oil vs. placebo	Weight loss and elevated superoxidase dismutase (SOD) levels.	RA/DB/parallel	[210]
Forty-five healthy women with obesity	2000 mg of NS oil with supplement	NS oil vs. placebo	Good effects of NS supplements in treating obesity.	RA/DB/crossover design	[212]
80 asthmatics patients	NS oil capsules 500 mg twice daily for 4 weeks	NS oil vs. placebo	NS oil supplementation, asthma control and pulmonary function improvement.	RA/DB/placebo-controlled trial	[190]

Non-alcoholic fatty liver disease (NAFLD); fasting blood sugar (FBS); cardiovascular disease (CVD); Randomized (RA); Double-blinded (DB); Randomized controlled trials (RCT); superoxidase dismutase (SOD).

## 7. Toxicological Properties

The seeds of the NS plant contain a wealth of beneficial elements. Several hepatic and renal enzymes and metabolites were unaffected by 50 mg/kg intraperitoneal NS seed extract in rats for five days [213]. Rats and mice given the seed oil orally at dosages up to

10 mL/kg showed no signs of death or overt toxicity after 48 h [214]. It was verified in a study, which found that giving rats a dosage of 10 mL/kg of fixed oil of NS orally for up to 12 weeks did not result in any deaths or appreciable changes to their vital liver enzymes [149]. It was determined that the LD<sub>50</sub> value of thymoquinone is 2.4 g/kg (range 1.52–3.77) [215]. For ninety days, mice given up to 0.03% of thymoquinone in their drinking water showed no toxicity, except for a notable drop in fasting plasma glucose concentration [215]. There was no evidence of harm when thymoquinone (at concentrations up to 0.03%) was added to the drinking water of mice for 90 days. However, there was a considerable reduction in fasting plasma glucose content. Topical corticosteroids were effective in treating several conditions [216]. To evaluate the safety of NS as an herbal remedy, healthy volunteers were administered 5 mL/day of NS oil for eight weeks. No significant adverse effects were observed on the kidney, gastrointestinal tract, or liver [217]. An additional clinical trial involving 39 obese men demonstrated that consuming NS seeds (3 mg daily for three months) had no discernible adverse effects [152]. Clinical investigations using NS seeds found no significant impact on blood creatinine or alanine aminotransferase (ALT) levels in people when given 2 g/day for 6 weeks [207].

Moreover, there was no discernible change in the renal or hepatic function of diabetic patients who took NS at doses of 1, 2, or 3 g/day for three months [218]. Patients with seasonal allergy rhinitis (AR) participated in a clinical experiment to assess the safety of NS consumption. Patients were instructed to take 250 mg daily for two weeks, after which they were to report any adverse effects. Furthermore, it was verified that nasal dryness was observed in patients treated with nasal drops containing NS oil for seasonal AR [219]. Both aspartate transaminase (AST) and alanine transaminase (ALT) enzyme levels were significantly increased only from the oil.

Contrarily, when crushed seeds were combined with the oil, the alkaline phosphate and  $\gamma$ -GT activities substantially increased. Therefore, NS is considered safe for therapeutic and dietary purposes [156]. Combining the usual diabetes treatment (medication, exercise, and a healthy diet) with NS tea (5 g/day) was the subject of a clinical investigation. For two months, patients with mild hypertension who took 200 or 400 mg/day of NS seed extract did not experience any significant side effects [206]. The findings showed that patients with type 2 diabetes had a realistic liver and kidney safety level. The overall number of leukocytes and platelets was unaffected by the consumption of NS oil [220]. Another clinical experiment investigated the potential for NS to have adverse effects or safety when used to treat childhood cancer. In addition to the standard chemotherapy, NS powder is administered to children aged 2–18 with acute lymphoblastic leukaemia at 40 mg/kg divided into two doses over three months. NS had fewer side effects than L-asparaginase and standard drugs such as prednisolone, daunorubicin, and vincristine [221]. These clinical results show that NS has the potential to be an effective natural anticancer medication and a vital alternative to L-asparaginase in the treatment of cancer-affected individuals.

In addition, no adverse side effects were reported when children infected with cestodes were given NS seeds as part of a clinical experiment looking at the seeds' anticestodal benefits [222]. Another research showed that interference with other cytochromes' substrates, including CYP2D6 and CYP3A4, led to a reduction in the absorption of dextromethorphan when NS (5 g/day) was used by healthy human volunteers [223]. NS may also impact the metabolism of numerous other medications, therefore care should be exercised [224]. In addition to its many positive functions and effects on biological systems, NS has been extensively studied to ascertain its toxicity. One of these studies was done to determine if NS seeds could harm liver tissue and enzymes. Serum levels of ALT and AST were not significantly altered by NS therapy. Researchers discovered that it mitigated toxicity by functioning as an antitoxic. According to the results, it is safe for living organisms [225,226]. Animal studies have shown that high doses of NS may harm the kidneys and liver. Taking NS while undergoing chemotherapy may also reduce the effectiveness of the medications.

Nevertheless, prolonged exposure to NS extracts may result in their toxicity to biological systems [4].

As a result of the numerous studies conducted to determine the safety of NS, its use in all biological systems is deemed relatively risk-free. In food and medicine, black seed is safe when used in modest doses for a short time. However, it harms living organisms when used in high quantities or over extended periods. Black seed, such as culinary seasoning, is probably safe for most people to eat in small amounts. When taken in small doses for a limited period for medical purposes, black seed oil and extract may be safe. Not enough information is available to determine whether more significant quantities, such as those used in medicine, are safe.

## 8. Conclusions and Future Recommendations

Anti-inflammatory medicinal herbs have shown beneficial effects in fighting inflammatory responses. A literature survey has demonstrated that NS has protective effects in inflammatory diseases. We discussed the examination of NS's anti-inflammatory properties in both experimental and clinical settings, with the findings from clinical settings being the more trustworthy. In vitro and in vivo studies have shown impressive pharmacological potential against chronic inflammatory diseases due to their high concentrations of TQ,  $\alpha$ -hederin, and oil extracts in NS. The anti-inflammatory qualities, widespread availability, affordability, sufficient potency, little or absent side effects, and enhanced safety and efficacy compared to synthetic alternatives make NS and its phytoconstituents advantageous. There are various mechanisms for the anti-inflammatory action of these secondary metabolites. The potential exists for the synergistic modulation of factors, enzymes, and proteins involved in the anti-inflammatory pathway and the potential for interference with these components within the inflammatory pathway. Such factors include interleukins, tumor necrosis, cyclooxygenases, lipooxygenases, nuclear factors, mitogen-activated protein, nitric oxide, prostaglandin, and others. The research suggests NS may be a potential anti-inflammatory drug for cardiovascular, diabetes, and asthma-related conditions. To date, clinical trials conducted with NS are limited. More clinical research with more participants and a meta-analysis might help resolve some disagreements. Further investigation is required to ascertain the optimal dose and duration of treatment necessary to establish the effectiveness and use of *Nigella sativa* in managing chronic inflammatory conditions.

**Author Contributions:** Conceptualization and methodology, S.W. and A.A.; writing—original draft preparation, S.W. and A.A. writing—review and editing, S.W. and A.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Deanship of Scientific Research at King Khalid University through the Large Research Groups Project under grant number (RGP.2/313/44).

**Acknowledgments:** The authors extend their appreciation to the Deanship of Scientific Research at King Khalid University for funding this work through the Large Research Groups Project under grant number (RGP.2/313/44).

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Alsayari, A.; Wahab, S. Genus Ziziphus for treating Chronic Inflammatory Diseases. *Saudi J. Biol. Sci.* **2021**, *28*, 6897–6914. [CrossRef] [PubMed]
2. Alsayari, A.; Muhsinah, A.B.; Almughaslah, D.; Annadurai, S.; Wahab, S. Pharmacological Efficacy of Ginseng against Respiratory Tract Infections. *Molecules* **2021**, *26*, 4095. [CrossRef] [PubMed]
3. Petruzzello, M. Black Cumin | Description, Plant, Seeds, Spice, Medicine, Uses, & Facts | Britannica. 2017. Available online: <https://www.britannica.com/plant/black-cumin> (accessed on 13 October 2023).
4. Yimer, E.M.; Tuem, K.B.; Karim, A.; Ur-Rehman, N.; Anwar, F. *Nigella sativa* L. (Black Cumin): A Promising Natural Remedy for Wide Range of Illnesses. *Evid.-Based Complement. Altern. Med.* **2019**, *2019*, 1528635. [CrossRef] [PubMed]
5. Tavakkoli, A.; Mahdian, V.; Razavi, B.M.; Hosseinzadeh, H. Review on Clinical Trials of Black Seed (*Nigella sativa*) and Its Active Constituent, Thymoquinone. *J. Pharmacopunct.* **2017**, *20*, 179–193.

6. Forouzanfar, F.; Fazly Bazzaz, B.S.; Hosseinzadeh, H. Black Cumin (*Nigella sativa*) and Its Constituent (Thymoquinone): A Review on Antimicrobial Effects. *Iran. J. Basic Med. Sci.* **2014**, *17*, 929–938.
7. Ahmad, A.; Husain, A.; Mujeeb, M.; Khan, S.A.; Najmi, A.K.; Siddique, N.A.; Damanhour, Z.A.; Anwar, F. A Review on Therapeutic Potential of *Nigella sativa*: A Miracle Herb. *Asian Pac. J. Trop. Biomed.* **2013**, *3*, 337–352. [[CrossRef](#)]
8. Sharma, N.; Ahirwar, D.; Jhade, D.; Gupta, S. Medicinal and Pharmacological Potential of *Nigella sativa*: A Review. *Ethnobot. Rev.* **2009**, *13*, 11.
9. Hadi, S.; Daryabeygi-Khotbehsara, R.; Mirmiran, P.; McVicar, J.; Hadi, V.; Soleimani, D.; Askari, G. Effect of *Nigella sativa* Oil Extract on Cardiometabolic Risk Factors in Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Phyther. Res.* **2021**, *35*, 3747–3755. [[CrossRef](#)]
10. Amizadeh, S.; Rashtchizadeh, N.; Khabbazi, A.; Ghorbanihaghjo, A.; Ebrahimi, A.-A.; Vatankhah, A.-M.; Malek Mahdavi, A.; Taghizadeh, M. Effect of *Nigella sativa* Oil Extracts on Inflammatory and Oxidative Stress Markers in Behcet’s Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Avicenna J. Phytomed.* **2020**, *10*, 181–189.
11. Corneanu, C.G.; Corneanu, M. Considerations on Human Evolution and on Species Origin Centers. *Oltenia Stud. Comunicări Stiințele Nat.* **2011**, *27*, 210–217.
12. Saad, B.; Said, O. *Greco-Arab and Islamic Herbal Medicine: Traditional System, Ethics, Safety, Efficacy, and Regulatory Issues*; Wiley: Hoboken, NJ, USA, 2011; ISBN 9780470474211.
13. Ved, D.K.; Goraya, G.S. *Demand and Supply of Medicinal Plants in India*; NMPB: New Delhi India; FRLHT: Bangalore, India, 2007; pp. 1–18.
14. Rabbani, M.A.; Ghafoor, A.; Masood, M.S. Narc-Kalonji: An Early Maturing and High Yielding Variety of *Nigella sativa* Released for Cultivation in Pakistan. *Pakistan J. Bot.* **2011**, *43*, 191–195.
15. Koochehi, A.A. Indigenous Knowledge in Agriculture with Particular Reference to Saffron Production in Iran. *Acta Hort.* **2004**, *650*, 175–182. [[CrossRef](#)]
16. Toma, C.C.; Simu, G.M.; Hanganu, D.; Olah, N.; Vata, F.M.G.; Hammami, C.; Hammami, M. Chemical Composition of the Tunisian *Nigella sativa*. Note II. Profile on Fatty Oil. *Farmacia* **2013**, *61*, 454–458.
17. Botnick, I.; Xue, W.; Bar, E.; Ibdah, M.; Schwartz, A.; Joel, D.M.; Lev, E.; Fait, A.; Lewinsohn, E. Distribution of Primary and Specialized Metabolites in *Nigella sativa* Seeds, a Spice with Vast Traditional and Historical Uses. *Molecules* **2012**, *17*, 10159–10177. [[CrossRef](#)] [[PubMed](#)]
18. Burdock, G.A. Assessment of Black Cumin (*Nigella sativa* L.) as a Food Ingredient and Putative Therapeutic Agent. *Regul. Toxicol. Pharmacol.* **2022**, *128*, 105088. [[CrossRef](#)]
19. Hoppe, B. *Handbuch des Arznei-und Gewürzpflanzenbaus*; Verein für Arznei-und Gewürzpflanzen Saluplanta: Aschersleben, Germany, 2009.
20. Paarakh, P.M. *Nigella sativa* Linn.—A Comprehensive Review. *Indian J. Nat. Prod. Resour.* **2010**, *1*, 409–429.
21. Al-Naqe, G.N.; Ismail, M.M.; Al-Zuba, A.S.; Esa, N.M. Nutrients Composition and Minerals Content of Three Different Samples of *Nigella sativa* L. Cultivated in Yemen. *Asian J. Biol. Sci.* **2009**, *2*, 43–48. [[CrossRef](#)]
22. Teuscher, E.; Bauermann, U.; Werner, M.; Brinckmann, J.A.; Lindenmaier, M.P.; Duke, J.A. Book Review: Medicinal Spices: A Handbook of Culinary Herbs, Spices, Spice Mixtures and Their Essential Oils. *Food Nutr. Bull.* **2006**, *27*, 271. [[CrossRef](#)]
23. Gashaw, Z. Status of Black Cumin (*Nigella sativa* L.) Research and Production in Ethiopia; A Review. *Int. J. For. Hortic.* **2020**, *6*, 20–29. [[CrossRef](#)]
24. Kifelew, H.; Fikere, D.; Lulseged, T.; Bekele, D.; Mitiku, H. *Wakjira Seed Spices Production Guideline*; Ethiopian Institute of Agricultural Research: Addis Ababa, Ethiopia, 2017; pp. 1–36.
25. Assefa, E. Adaptability Study of Black Cumin (*Nigella sativa* L.) Varieties in the Mid and High Land Areas of Kaffa Zone, South West Ethiopia. *Agric. For. Fish.* **2015**, *4*, 14. [[CrossRef](#)]
26. Hammo, Y.H. Effect of Very High Levels of Nitrogen and Phosphorus Fertilizers, Pinching, and Seed Rate Sowing on Growth, Seed Yield and Components of *Nigella sativa* L. 2—Seed Components. *Mesopotamia J. Agric.* **2008**, *36*, 2–11. [[CrossRef](#)]
27. Heiss, A.G.; Stika, H.-P.; De Zorzi, N.; Jursa, M. *Nigella* in the Mirror of Time: A Brief Attempt to Draw a Genus’ Ethnohistorical Portrait. *Sylt Kastanas Festschrift Helmut Johannes Kroll* **2013**, *69*, 147–169. [[CrossRef](#)]
28. Marshall, H.S.; Thompson, R.C. A Dictionary of Assyrian Botany. *Kew Bull.* **1951**, *6*, 27. [[CrossRef](#)]
29. Fadl, M. Comparison between Archaeobotany of Inland and Coastal Sites in the Eastern Desert of Egypt in 300 B.C.–700 A.D. *Int. Res. J. Plant Sci.* **2013**, *4*, 117–132.
30. Van der Veen, M. Formation Processes of Desiccated and Carbonized Plant Remains—The Identification of Routine Practice. *J. Archaeol. Sci.* **2007**, *34*, 968–990. [[CrossRef](#)]
31. Osbaldeston, T.A. *De Materia Medica—Introduction*; Wechelus: Paris, France, 2000.
32. Srinivasan, K. Cumin (*Cuminum cyminum*) and Black Cumin (*Nigella sativa*) Seeds: Traditional Uses, Chemical Constituents, and Nutraceutical Effects. *Food Qual. Saf.* **2018**, *2*, 1–16. [[CrossRef](#)]
33. Bühler, A.; Römer, T.; Schmid, K. *The Joseph Story between Egypt and Israel*; Mohr Siebeck: Tübingen, Germany, 2021.
34. Al-Bukhari, M.I.; Sahi, A.B. *The Collection of Authentic Sayings of Prophet Mohammad (Peace Be upon Him), Division 71 on Medicine*; Hilal Yayinlari: Ankara, Turkey, 1976.
35. Bhatti, I.; Zubair, H.; Bakhsh, M.S.; Akhlaq, M. The Scientific Importance of *Nigella sativa* (Kalonji) and Honey in Accordance with Tib-E-Nabvi. *Gomal Univ. J. Res.* **2013**, *29*, 27–30.

36. Heiss, A.G.; Oegg, K. The Oldest Evidence of *Nigella Damascena* L. (Ranunculaceae) and Its Possible Introduction to Central Europe. *Veg. Hist. Archaeobot.* **2005**, *14*, 562–570. [[CrossRef](#)]
37. Geraci, A.; Polizzano, V.; Schicchi, R. Ethnobotanical Uses of Wild Taxa as Galactagogues in Sicily (Italy). *Acta Soc. Bot. Pol.* **2018**, *87*, 1–18. [[CrossRef](#)]
38. Jarić, S.; Mitrović, M.; Karadžić, B.; Kostić, O.; Djurjević, L.; Pavlović, M.; Pavlović, P. Plant Resources Used in Serbian Medieval Medicine. Ethnobotany and Ethnomedicine. *Genet. Resour. Crop Evol.* **2014**, *61*, 1359–1379. [[CrossRef](#)]
39. Leporatti, M.L.; Ghedira, K. Comparative Analysis of Medicinal Plants Used in Traditional Medicine in Italy and Tunisia. *J. Ethnobiol. Ethnomed.* **2009**, *5*, 31. [[CrossRef](#)]
40. Abdelmajid, K.; Mohamed, L.; Sidi, A.E.; Ben, M. Plant Resources Use in the Province of Taza (North of Morocco) Evaluation and Sustainable Exploitation of Local Endemic Phyto-genetic Resources View Project Medicinal Plants View Project. *ProEnvironment Promediu* **2011**, *4*, 347–356.
41. Bahmani, M.; Eftekhari, Z.; Jelodari, M.; Saki, K.; Abdollahi, R.; Majlesi, M.; Rafieian-Kopaei, M.; Rasouli, S. Effect of Iranian Herbal Medicines in Dysmenorrhea Phytotherapy. *J. Chem. Pharm. Res.* **2015**, *7*, 519–526.
42. Ali-Shtayeh, M.S.; Jamous, R.M.; Jamous, R.M. Plants Used during Pregnancy, Childbirth, Postpartum and Infant Healthcare in Palestine. *Complement. Ther. Clin. Pract.* **2015**, *21*, 84–93. [[CrossRef](#)]
43. Khajoei Nasab, F.; Khosravi, A.R. Ethnobotanical Study of Medicinal Plants of Sirjan in Kerman Province, Iran. *J. Ethnopharmacol.* **2014**, *154*, 190–197. [[CrossRef](#)] [[PubMed](#)]
44. Kartal, Ç.; Güneş, F. Medicinal Plants Used in Meriç Town from Turkey. *Indian J. Pharm. Educ. Res.* **2017**, *51*, S249–S253. [[CrossRef](#)]
45. Jaradat, N.A.; Al-Ramahi, R.; Zaid, A.N.; Ayesh, O.I.; Eid, A.M. Ethnopharmacological Survey of Herbal Remedies Used for Treatment of Various Types of Cancer and Their Methods of Preparations in the West Bank-Palestine. *BMC Complement. Altern. Med.* **2016**, *16*, 93. [[CrossRef](#)]
46. Pavela, R.; Chermenskaya, T. Potential Insecticidal Activity of Extracts from 18 Species of Medicinal Plants on Larvae of *Spodoptera Littoralis*—Short Communication. *Plant Prot. Sci.* **2004**, *40*, 145–150. [[CrossRef](#)]
47. Sharif, H.R.; Abbas, S.; Majeed, H.; Safdar, W.; Shamoan, M.; Khan, M.A.; Shoaib, M.; Raza, H.; Haider, J. Formulation, Characterization and Antimicrobial Properties of Black Cumin Essential Oil Nanoemulsions Stabilized by OSA Starch. *J. Food Sci. Technol.* **2017**, *54*, 3358–3365. [[CrossRef](#)]
48. Shehata, T.M.; Almostafa, M.M.; Elsewedy, H.S. Development and Optimization of *Nigella sativa* Nanoemulsion Loaded with Pioglitazone for Hypoglycemic Effect. *Polymers* **2022**, *14*, 3021. [[CrossRef](#)]
49. Hossain, M.S.; Urbi, Z.; Evamoni, F.Z.; Zohora, F.T.; Rahman, K.M.H. A Secondary Research on Medicinal Plants Mentioned in the Holy Qur’an. *J. Med. Plants* **2016**, *15*, 81–97.
50. Urbi, Z.; Hossain, S.; Hafizur Rahman, K.M.; Zayed, T.M. Grape: A Medicinal Fruit Species in the Holy Qur’an and Its Ethnomedicinal Importance. *World Appl. Sci. J.* **2014**, *30*, 253–265. [[CrossRef](#)]
51. Alade, G.O.; Ajibesin, K.K. Herbal Medicine: Clerics’ Knowledge in a Sub Urban Center in Niger Delta, Nigeria—A Pilot Study. *J. Pharm. Pharmacogn. Res.* **2017**, *5*, 200–216.
52. Tariq, M. *Nigella sativa* Seeds: Folklore Treatment in Modern Day Medicine. *Saudi J. Gastroenterol.* **2008**, *14*, 105–106. [[CrossRef](#)]
53. Ali, S.A.; Parveen, N.; Ali, A.S. Links between the Prophet Muhammad (PBUH) Recommended Foods and Disease Management: A Review in the Light of Modern Superfoods. *Int. J. Health Sci.* **2018**, *12*, 61–69.
54. Shabana, A.; El-Menyar, A.; Asim, M.; Al-Azzeh, H.; Al Thani, H. Cardiovascular Benefits of Black Cumin (*Nigella sativa*). *Cardiovasc. Toxicol.* **2013**, *13*, 9–21. [[CrossRef](#)]
55. Yuan, H.; Ma, Q.; Ye, L.; Piao, G. The Traditional Medicine and Modern Medicine from Natural Products. *Molecules* **2016**, *21*, 559. [[CrossRef](#)] [[PubMed](#)]
56. Cheikh-Rouhou, S.; Besbes, S.; Hentati, B.; Blecker, C.; Deroanne, C.; Attia, H. *Nigella sativa* L.: Chemical Composition and Physicochemical Characteristics of Lipid Fraction. *Food Chem.* **2007**, *101*, 673–681. [[CrossRef](#)]
57. Nickavar, B.; Mojab, F.; Javidnia, K.; Roodgar Amoli, M.A. Chemical Composition of the Fixed and Volatile Oils of *Nigella sativa* L. from Iran. *Zeitschrift Naturforsch.-Sect. C J. Biosci.* **2003**, *58*, 629–631. [[CrossRef](#)]
58. Venkatachallam, S.K.T.; Pattekhan, H.; Divakar, S.; Kadimi, U.S. Chemical Composition of *Nigella sativa* L. Seed Extracts Obtained by Supercritical Carbon Dioxide. *J. Food Sci. Technol.* **2010**, *47*, 598–605. [[CrossRef](#)]
59. Jrah Harzallah, H.; Kouidhi, B.; Flamini, G.; Bakhrouf, A.; Mahjoub, T. Chemical Composition, Antimicrobial Potential against Cariogenic Bacteria and Cytotoxic Activity of Tunisian *Nigella sativa* Essential Oil and Thymoquinone. *Food Chem.* **2011**, *129*, 1469–1474. [[CrossRef](#)]
60. Ghedira, K. La Nigelle Cultivée: *Nigella sativa* L. (Ranunculaceae). *Phytotherapie* **2006**, *4*, 220–226. [[CrossRef](#)]
61. Houghton, P.J.; Zarka, R.; De Las Heras, B.; Hoult, J.R.S. Fixed Oil of *Nigella sativa* and Derived Thymoquinone Inhibit Eicosanoid Generation in Leukocytes and Membrane Lipid Peroxidation. *Planta Med.* **1995**, *61*, 33–36. [[CrossRef](#)] [[PubMed](#)]
62. El-Dakhakhny, M. Studies on the Chemical Constitution of Egyptian *Nigella sativa* L. Seeds. II 1) the Essential Oil. *Planta Med.* **1963**, *11*, 465–470. [[CrossRef](#)]
63. Nathan, C.; Ding, A. Nonresolving Inflammation. *Cell* **2010**, *140*, 871–882. [[CrossRef](#)]
64. Burits, M.; Asres, K.; Bucar, F. The Antioxidant Activity of the Essential Oils of *Artemisia Afra*, *Artemisia Abyssinica* and *Juniperus Procera*. *Phyther. Res.* **2001**, *15*, 103–108. [[CrossRef](#)] [[PubMed](#)]
65. Begum, S.; Mannan, A. A Review on *Nigella sativa*: A Marvel Herb. *J. Drug Deliv. Ther.* **2020**, *10*, 213–219. [[CrossRef](#)]

66. Keyhanmanesh, R.; Bagban, H.; Nazemiyeh, H.; Babil, F.M.; Alipour, M.R.; Ahmady, M. The Relaxant Effects of Different Methanolic Fractions of *Nigella sativa* on Guinea Pig Tracheal Chains. *Iran. J. Basic Med. Sci.* **2013**, *16*, 123–128.
67. Bordoni, L.; Fedeli, D.; Nasuti, C.; Maggi, F.; Papa, F.; Wabitsch, M.; De Caterina, R.; Gabbianelli, R. Antioxidant and Anti-Inflammatory Properties of *Nigella sativa* Oil in Human Pre-Adipocytes. *Antioxidants* **2019**, *8*, 51. [[CrossRef](#)] [[PubMed](#)]
68. Salem, M.L. Immunomodulatory and Therapeutic Properties of the *Nigella sativa* L. Seed. *Int. Immunopharmacol.* **2005**, *5*, 1749–1770. [[CrossRef](#)]
69. Khaldi, T.; Chekchaki, N.; Boumendjel, M.; Taibi, F.; Abdellaoui, M.; Messarah, M.; Boumendjel, A. Ameliorating Effects of *Nigella sativa* Oil on Aggravation of Inflammation, Oxidative Stress and Cytotoxicity Induced by Smokeless Tobacco Extract in an Allergic Asthma Model in Wistar Rats. *Allergol. Immunopathol.* **2018**, *46*, 472–481. [[CrossRef](#)] [[PubMed](#)]
70. Tuna, H.I.; Babadag, B.; Ozkaraman, A.; Balci Alparslan, G. Investigation of the Effect of Black Cumin Oil on Pain in Osteoarthritis Geriatric Individuals. *Complement. Ther. Clin. Pract.* **2018**, *31*, 290–294. [[CrossRef](#)] [[PubMed](#)]
71. Ahmed, J.H.; Kadhim, S.N.; Al-Hamdi, K.I. The Effectiveness of *Nigella sativa*, Methotrexate and Their Combination in the Treatment of Moderate to Severe Psoriasis. *J. Clin. Exp. Investig.* **2015**, *5*, 521–528. [[CrossRef](#)]
72. Badri, W.; El Asbahani, A.; Miladi, K.; Baraket, A.; Agusti, G.; Nazari, Q.A.; Errachid, A.; Fessi, H.; Elaissari, A. Poly ( $\epsilon$ -Caprolactone) Nanoparticles Loaded with Indomethacin and *Nigella sativa* L. Essential Oil for the Topical Treatment of Inflammation. *J. Drug Deliv. Sci. Technol.* **2018**, *46*, 234–242. [[CrossRef](#)]
73. Rizvi, A.; Mahdi, A.A.; Wahab, S.; Mishra, A. Protective Effects of *Butea frondosa* Leaves against Stress Induced Immune Impairment in Sprague Dawley Rats. *Pak. J. Pharm. Sci.* **2018**, *31*, 2457–2462. [[PubMed](#)]
74. Bascones-Martinez, A.; Mattila, R.; Gomez-Font, R.; Meurman, J.H. Immunomodulatory Drugs: Oral and Systemic Adverse Effects. *Med. Oral Patol. Oral Cir. Bucal* **2014**, *19*, e24–e31. [[CrossRef](#)]
75. Haq, A.; Abdullatif, M.; Lobo, P.I.; Khabar, K.S.A.; Sheth, K.V.; Al-Sedairy, S.T. *Nigella sativa*: Effect on Human Lymphocytes and Polymorphonuclear Leukocyte Phagocytic Activity. *Immunopharmacology* **1995**, *30*, 147–155. [[CrossRef](#)]
76. Taifa, S.; Muhee, A.; Bhat, R.A.; Nabi, S.U.I.; Roy, A.; Rather, G.A.; Khan, A.A.; Bashir, S.M.; Patwekar, M.; Wahab, S.; et al. Evaluation of Therapeutic Efficacy of Copper Nanoparticles in *Staphylococcus Aureus*—Induced Rat Mastitis Model. *J. Nanomater.* **2022**, *2022*, 7124114. [[CrossRef](#)]
77. Islam, S.N.; Begum, P.; Ahsan, T.; Huque, S.; Ahsan, M. Immunosuppressive and Cytotoxic Properties of *Nigella sativa*. *Phyther. Res.* **2004**, *18*, 395–398. [[CrossRef](#)]
78. Swamy, S.M.K.; Tan, B.K.H. Cytotoxic and Immunopotentiating Effects of Ethanolic Extract of *Nigella sativa* L. Seeds. *J. Ethnopharmacol.* **2000**, *70*, 1–7. [[CrossRef](#)] [[PubMed](#)]
79. Twilley, D.; Rademan, S.; Lall, N. A Review on Traditionally Used South African Medicinal Plants, Their Secondary Metabolites and Their Potential Development into Anticancer Agents. *J. Ethnopharmacol.* **2020**, *261*, 113101. [[CrossRef](#)] [[PubMed](#)]
80. Wahab, S.; Ahmad, I.; Irfan, S.; Baig, M.H.; Farouk, A.-E.; Dong, J.-J. Use of Natural Compounds as a Potential Therapeutic Agent Against COVID-19. *Curr. Pharm. Des.* **2021**, *27*, 1144–1152. [[CrossRef](#)]
81. Alshehri, S.A.; Wahab, S.; Abullais, S.S.; Das, G.; Hani, U.; Ahmad, W.; Amir, M.; Ahmad, A.; Kandasamy, G.; Vasudevan, R. Pharmacological Efficacy of *Tamarix Aphylla*: A Comprehensive Review. *Plants* **2022**, *11*, 118. [[CrossRef](#)] [[PubMed](#)]
82. Wahab, S.; Hussain, A. Cytokines as Targets for Immunomodulation. *Int. J. Pharm. Pharm. Sci.* **2013**, *5*, 60–64.
83. Dhanasekaran, S. Phytochemical Characteristics of Aerial Part of *Cissus quadrangularis* (L) and Its in-Vitro Inhibitory Activity against Leukemic Cells and Antioxidant Properties. *Saudi J. Biol. Sci.* **2020**, *27*, 1302–1309. [[CrossRef](#)]
84. Jadhav, V.; Bhagare, A.; Wahab, S.; Lokhande, D.; Vaidya, C.; Dhayagade, A.; Khalid, M.; Aher, J.; Mezni, A.; Dutta, M. Green Synthesized Calcium Oxide Nanoparticles (CaO NPs) Using Leaves Aqueous Extract of Moringa Oleifera and Evaluation of Their Antibacterial Activities. *J. Nanomater.* **2022**, *2022*, 9047507. [[CrossRef](#)]
85. Hani, U.; Osmani, R.A.M.; Yasmin, S.; Gowda, B.H.J.; Ather, H.; Ansari, M.Y.; Siddiqua, A.; Ghazwani, M.; Fatease, A.A.; Alamri, A.H.; et al. Novel Drug Delivery Systems as an Emerging Platform for Stomach Cancer Therapy. *Pharmaceutics* **2022**, *14*, 1576. [[CrossRef](#)]
86. Shoaib, A.; Tabish, M.; Ali, S.; Arafah, A.; Wahab, S.; Almarshad, F.M.; Rashid, S.; Rehman, M.U. Dietary Phytochemicals in Cancer Signalling Pathways: Role of MiRNA Targeting. *Curr. Med. Chem.* **2021**, *28*, 8036–8067. [[CrossRef](#)]
87. Akhtar, M.F.; Saleem, A.; Rasul, A.; Faran Ashraf Baig, M.M.; Bin-Jumah, M.; Abdel Daim, M.M. Anticancer Natural Medicines: An Overview of Cell Signaling and Other Targets of Anticancer Phytochemicals. *Eur. J. Pharmacol.* **2020**, *888*, 173488. [[CrossRef](#)]
88. Palanisamy, N.; Manian, S. Protective Effects of *Asparagus racemosus* on Oxidative Damage in Isoniazid-Induced Hepatotoxic Rats: An in Vivo Study. *Toxicol. Ind. Health* **2012**, *28*, 238–244. [[CrossRef](#)]
89. Ahmad, I.; Irfan, S.; Abohashrh, M.; Wahab, S.; Abullais, S.S.; Javali, M.A.; Nisar, N.; Alam, M.M.; Srivastava, S.; Saleem, M.; et al. Inhibitory Effect of *Nepeta Deflersiana* on Climax Bacterial Community Isolated from the Oral Plaque of Patients with Periodontal Disease. *Molecules* **2021**, *26*, 202. [[CrossRef](#)]
90. Khalid, M.; Alqarni, M.H.; Alsayari, A.; Foudah, A.I.; Aljarba, T.M.; Mukim, M.; Alamri, M.A.; Abullais, S.S.; Wahab, S. Anti-Diabetic Activity of Bioactive Compound Extracted from *Spondias Mangifera* Fruit: In-Vitro and Molecular Docking Approaches. *Plants* **2022**, *11*, 562. [[CrossRef](#)] [[PubMed](#)]
91. Juárez, P. Plant-Derived Anticancer Agents: A Promising Treatment for Bone Metastasis. *Bonekey Rep.* **2014**, *3*, 599. [[CrossRef](#)] [[PubMed](#)]

92. Ghosheh, O.A.; Houdi, A.A.; Crooks, P.A. High Performance Liquid Chromatographic Analysis of the Pharmacologically Active Quinones and Related Compounds in the Oil of the Black Seed (*Nigella sativa* L.). *J. Pharm. Biomed. Anal.* **1999**, *19*, 757–762. [[CrossRef](#)]
93. Ali, B.H.; Blunden, G. Pharmacological and Toxicological Properties of *Nigella sativa*. *Phyther. Res.* **2003**, *17*, 299–305. [[CrossRef](#)]
94. Mehraj, T.; Elkanayati, R.M.; Farooq, I.; Mir, T.M. A Review of *Nigella sativa* and Its Active Principles as Anticancer Agents. In *Black Seeds (Nigella sativa)*; Elsevier: Amsterdam, The Netherlands, 2022; pp. 91–118.
95. Jia, S.S.; Xi, G.P.; Zhang, M.; Chen, Y.B.; Lei, B.; Dong, X.S.; Yang, Y.M. Induction of Apoptosis by D-Limonene Is Mediated by Inactivation of Akt in LS174T Human Colon Cancer Cells. *Oncol. Rep.* **2013**, *29*, 349–354. [[CrossRef](#)]
96. Swamy, S.M.K.; Huat, B.T.K. Intracellular Glutathione Depletion and Reactive Oxygen Species Generation Are Important in  $\alpha$ -Hederin-Induced Apoptosis of P388 Cells. *Mol. Cell. Biochem.* **2003**, *245*, 127–139.
97. Effenberger, K.; Breyer, S.; Schobert, R. Terpene Conjugates of the *Nigella sativa* Seed-Oil Constituent Thymoquinone with Enhanced Efficacy in Cancer Cells. *Chem. Biodivers.* **2010**, *7*, 129–139. [[CrossRef](#)]
98. Farah, I.O.; Begum, R.A. Effect of *Nigella sativa* (*N. sativa* L.) and Oxidative Stress on the Survival Pattern of MCF-7 Breast Cancer Cells. *Biomed. Sci. Instrum.* **2003**, *39*, 359–364.
99. Gali-Muhtasib, H.; Diab-Assaf, M.; Boltze, C.; Al-Hmaira, J.; Hartig, R.; Roessner, A.; Schneider-Stock, R. Thymoquinone Extracted from Black Seed Triggers Apoptotic Cell Death in Human Colorectal Cancer Cells via a P53-Dependent Mechanism. *Int. J. Oncol.* **2004**, *25*, 857–866. [[PubMed](#)]
100. Salim, E.I.; Fukushima, S. Chemopreventive Potential of Volatile Oil from Black Cumin (*Nigella sativa* L.) Seeds against Rat Colon Carcinogenesis. *Nutr. Cancer* **2003**, *45*, 195–202. [[CrossRef](#)] [[PubMed](#)]
101. Rooney, S.; Ryan, M.F. Modes of Action of Alpha-Hederin and Thymoquinone, Active Constituents of *Nigella sativa*, against HEP-2 Cancer Cells. *Anticancer Res.* **2005**, *25*, 4255–4259. [[PubMed](#)]
102. Chehl, N.; Chipitsyna, G.; Gong, Q.; Yeo, C.J.; Arafat, H.A. Anti-Inflammatory Effects of the *Nigella sativa* Seed Extract, Thymoquinone, in Pancreatic Cancer Cells. *HPB* **2009**, *11*, 373–381. [[CrossRef](#)]
103. Association, A.D. Diagnosis and Classification of Diabetes Mellitus. *Diabetes Care* **2009**, *32*, S62–S67. [[CrossRef](#)] [[PubMed](#)]
104. Kifle, Z.D.; Abdelwuhab, M.; Melak, A.D.; Genet, G.; Meseret, T.; Adugna, M. Pharmacological Evaluation of Medicinal Plants with Antidiabetic Activities in Ethiopia: A Review. *Metab. Open* **2022**, *13*, 100174. [[CrossRef](#)]
105. Patel, D.K.; Kumar, R.; Laloo, D.; Hemalatha, S. Diabetes Mellitus: An Overview on Its Pharmacological Aspects and Reported Medicinal Plants Having Antidiabetic Activity. *Asian Pac. J. Trop. Biomed.* **2012**, *2*, 411–420. [[CrossRef](#)]
106. Kumar, J.A.; Tiwari, A.K.; Ali, A.Z.; Madhusudhana, K.; Reddy, B.S.; Ramakrishna, S.; China Raju, B. New Antihyperglycemic,  $\alpha$ -Glucosidase Inhibitory, and Cytotoxic Derivatives of Benzimidazoles. *J. Enzyme Inhib. Med. Chem.* **2010**, *25*, 80–86. [[CrossRef](#)] [[PubMed](#)]
107. Ahmad, W.; Amir, M.; Ahmad, A.; Ali, A.; Ali, A.; Wahab, S.; Barkat, H.A.; Ansari, M.A.; Sarafroz, M.; Ahmad, A.; et al. *Aegle Marmelos* Leaf Extract Phytochemical Analysis, Cytotoxicity, *in Vitro* Antioxidant and Antidiabetic Activities. *Plants* **2021**, *10*, 2573. [[CrossRef](#)] [[PubMed](#)]
108. Derosa, G.; Maffioli, P.  $\alpha$ -Glucosidase Inhibitors and Their Use in Clinical Practice. *Arch. Med. Sci.* **2012**, *8*, 899–906. [[CrossRef](#)]
109. Asghari, B.; Salehi, P.; Farimani, M.M.; Ebrahimi, S.N.  $\alpha$ -Glucosidase Inhibitors from Fruits of *Rosa canina* L. *Rec. Nat. Prod.* **2015**, *9*, 276–283.
110. Mohebbati, R.; Abbasnezhad, A. Effects of *Nigella sativa* on Endothelial Dysfunction in Diabetes Mellitus: A Review. *J. Ethnopharmacol.* **2020**, *252*, 112585. [[CrossRef](#)]
111. Hamdan, A.; Idrus, R.H.; Mokhtar, M.H. Effects of *Nigella sativa* on Type-2 Diabetes Mellitus: A Systematic Review. *Int. J. Environ. Res. Public Health* **2019**, *16*, 4911. [[CrossRef](#)] [[PubMed](#)]
112. Khader, M.; Eckl, P.M. Thymoquinone: An Emerging Natural Drug with a Wide Range of Medical Applications. *Iran. J. Basic Med. Sci.* **2014**, *17*, 950–957. [[PubMed](#)]
113. Abdelrazek, H.M.A.; Kilany, O.E.; Muhammad, M.A.A.; Tag, H.M.; Abdelazim, A.M. Black Seed Thymoquinone Improved Insulin Secretion, Hepatic Glycogen Storage, and Oxidative Stress in Streptozotocin-Induced Diabetic Male Wistar Rats. *Oxid. Med. Cell. Longev.* **2018**, *2018*, 8104165. [[CrossRef](#)] [[PubMed](#)]
114. Ahmad, S.; Beg, Z.H. Elucidation of Mechanisms of Actions of Thymoquinone-Enriched Methanolic and Volatile Oil Extracts from *Nigella sativa* against Cardiovascular Risk Parameters in Experimental Hyperlipidemia. *Lipids Health Dis.* **2013**, *12*, 86. [[CrossRef](#)] [[PubMed](#)]
115. Chen, L.H. *Nutritional Aspects of Aging*; CRC Press: Boca Raton, FL, USA, 2018; Volume 1, ISBN 9781351083584.
116. Stehbens, W.E. An Appraisal of Cholesterol Feeding in Experimental Atherogenesis. *Prog. Cardiovasc. Dis.* **1986**, *29*, 107–128. [[CrossRef](#)]
117. Farkhondeh, T.; Samarghandian, S.; Azimin-Nezhad, M.; Samini, F. Effect of Chrysin on Nociception in Formalin Test and Serum Levels of Noradrenalin and Corticosterone in Rats. *Int. J. Clin. Exp. Med.* **2015**, *8*, 2465–2470. [[PubMed](#)]
118. Samarghandian, S.; Azimi-Nezhad, M.; Borji, A.; Farkhondeh, T. Effect of Crocin on Aged Rat Kidney through Inhibition of Oxidative Stress and Proinflammatory State. *Phyther. Res.* **2016**, *30*, 1345–1353. [[CrossRef](#)]
119. Samarghandian, S.; Azimini-Nezhad, M.; Farkhondeh, T. The Effects of *Zataria Multiflora* on Blood Glucose, Lipid Profile and Oxidative Stress Parameters in Adult Mice During Exposure to Bisphenol A. *Cardiovasc. Hematol. Disord. Targets* **2016**, *16*, 41–46. [[CrossRef](#)]

120. Shafiq, H.; Ahmad, A.; Masud, T.; Kaleem, M. Cardio-Protective and Anti-Cancer Therapeutic Potential of *Nigella sativa*. *Iran. J. Basic Med. Sci.* **2014**, *17*, 967–980.
121. Mansour, M.A.; Nagi, M.N.; El-Khatib, A.S.; Al-Bekairi, A.M. Effects of Thymoquinone on Antioxidant Enzyme Activities, Lipid Peroxidation and Dt-Diaphorase in Different Tissues of Mice: A Possible Mechanism of Action. *Cell Biochem. Funct.* **2002**, *20*, 143–151. [[CrossRef](#)] [[PubMed](#)]
122. Nagi, M.N.; Mansour, M.A. Protective Effect of Thymoquinone against Doxorubicin-Induced Cardiotoxicity in Rats: A Possible Mechanism of Protection. *Pharmacol. Res.* **2000**, *41*, 283–289. [[CrossRef](#)]
123. Khalife, K.H.; Lupidi, G. Reduction of Hypervalent States of Myoglobin and Hemoglobin to Their Ferrous Forms by Thymoquinone: The Role of GSH, NADH and NADPH. *Biochim. Biophys. Acta-Gen. Subj.* **2008**, *1780*, 627–637. [[CrossRef](#)]
124. Liu, H.; Liu, H.Y.; Jiang, Y.N.; Li, N. Protective Effect of Thymoquinone Improves Cardiovascular Function, and Attenuates Oxidative Stress, Inflammation and Apoptosis by Mediating the PI3K/Akt Pathway in Diabetic Rats. *Mol. Med. Rep.* **2016**, *13*, 2836–2842. [[CrossRef](#)]
125. Ramadan, M.F. Nutritional Value, Functional Properties and Nutraceutical Applications of Black Cumin (*Nigella sativa* L.): An Overview. *Int. J. Food Sci. Technol.* **2007**, *42*, 1208–1218. [[CrossRef](#)]
126. Beheshti, F.; Hosseini, M.; Vafaee, F.; Shafei, M.N.; Soukhtanloo, M. Feeding of *Nigella sativa* during Neonatal and Juvenile Growth Improves Learning and Memory of Rats. *J. Tradit. Complement. Med.* **2016**, *6*, 146–152. [[CrossRef](#)]
127. Cascella, M.; Bimonte, S.; Barbieri, A.; Del Vecchio, V.; Muzio, M.R.; Vitale, A.; Benincasa, G.; Ferriello, A.B.; Azzariti, A.; Arra, C.; et al. Dissecting the Potential Roles of *Nigella sativa* and Its Constituent Thymoquinone on the Prevention and on the Progression of Alzheimer’s Disease. *Front. Aging Neurosci.* **2018**, *10*, 1208–1218. [[CrossRef](#)] [[PubMed](#)]
128. Khan, M.I.; Ahmad, M.F.; Ahmad, I.; Ashfaq, F.; Wahab, S.; Alsayegh, A.A.; Kumar, S.; Hakeem, K.R. Arsenic Exposure through Dietary Intake and Associated Health Hazards in the Middle East. *Nutrients* **2022**, *14*, 2136. [[CrossRef](#)]
129. Zhang, Y.; Chen, H.; Li, R.; Sterling, K.; Song, W. Amyloid  $\beta$ -Based Therapy for Alzheimer’s Disease: Challenges, Successes and Future. *Signal Transduct. Target. Ther.* **2023**, *8*, 248. [[CrossRef](#)]
130. Selkoe, D.J. Alzheimer’s Disease: Genes, Proteins, and Therapy. *Physiol. Rev.* **2001**, *81*, 741–766. [[CrossRef](#)]
131. Elibol, B.; Beker, M.; Terzioglu-Usak, S.; Dalli, T.; Kilic, U. Thymoquinone Administration Ameliorates Alzheimer’s Disease-like Phenotype by Promoting Cell Survival in the Hippocampus of Amyloid Beta1–42 Infused Rat Model. *Phytomedicine* **2020**, *79*, 153324. [[CrossRef](#)] [[PubMed](#)]
132. Cobourne-Duval, M.K.; Taka, E.; Mendonca, P.; Soliman, K.F.A. Thymoquinone Increases the Expression of Neuroprotective Proteins While Decreasing the Expression of Pro-Inflammatory Cytokines and the Gene Expression NF $\kappa$ B Pathway Signaling Targets in LPS/IFN $\gamma$ -Activated BV-2 Microglia Cells. *J. Neuroimmunol.* **2018**, *320*, 87–97. [[CrossRef](#)] [[PubMed](#)]
133. Alhibshi, A.H.; Odawara, A.; Suzuki, I. Neuroprotective Efficacy of Thymoquinone against Amyloid Beta-Induced Neurotoxicity in Human Induced Pluripotent Stem Cell-Derived Cholinergic Neurons. *Biochem. Biophys. Rep.* **2019**, *17*, 122–126. [[CrossRef](#)] [[PubMed](#)]
134. Poorgholam, P.; Yaghmaei, P.; Hajebrahimi, Z. Thymoquinone Recovers Learning Function in a Rat Model of Alzheimer’s Disease. *Avicenna J. Phytomed.* **2018**, *8*, 188–197. [[PubMed](#)]
135. El-Naggar, T.; Gómez-Serranillos, M.P.; Palomino, O.M.; Arce, C.; Carretero, M.E. *Nigella sativa* L. Seed Extract Modulates the Neurotransmitter Amino Acids Release in Cultured Neurons in Vitro. *J. Biomed. Biotechnol.* **2010**, *2010*, 398312. [[CrossRef](#)]
136. Sandhua, K.S.; Cranab, A. Evaluation of Anti Parkinson’S Activity of *Nigella sativa* (Kalonji) Seeds in Chlorpromazineinduced Experimental Animal Model. *Int. J. Pharm. Pharm. Sci.* **2013**, *5*, 884–888.
137. Hosseinzadeh, H.; Parvardeh, S.; Asl, M.N.; Sadeghnia, H.R.; Ziaee, T. Effect of Thymoquinone and *Nigella sativa* Seeds Oil on Lipid Peroxidation Level during Global Cerebral Ischemia-Reperfusion Injury in Rat Hippocampus. *Phytomedicine* **2007**, *14*, 621–627. [[CrossRef](#)]
138. Balbaa, M.; Abdulmalek, S.A.; Khalil, S. Oxidative Stress and Expression of Insulin Signaling Proteins in the Brain of Diabetic Rats: Role of *Nigella sativa* Oil and Antidiabetic Drugs. *PLoS ONE* **2017**, *12*, e0172429. [[CrossRef](#)]
139. Bray, G.A.; Frühbeck, G.; Ryan, D.H.; Wilding, J.P.H. Management of Obesity. *Lancet* **2016**, *387*, 1947–1956. [[CrossRef](#)]
140. WOF. *One Billion People Globally Estimated to Be Living with Obesity by 2030*; World Obesity Federation: London, UK, 2020.
141. Jung, U.J.; Choi, M.S. Obesity and Its Metabolic Complications: The Role of Adipokines and the Relationship between Obesity, Inflammation, Insulin Resistance, Dyslipidemia and Nonalcoholic Fatty Liver Disease. *Int. J. Mol. Sci.* **2014**, *15*, 6184–6223. [[CrossRef](#)] [[PubMed](#)]
142. Kushner, R.F. Weight Loss Strategies for Treatment of Obesity: Lifestyle Management and Pharmacotherapy. *Prog. Cardiovasc. Dis.* **2018**, *61*, 246–252. [[CrossRef](#)]
143. Hasani-Ranjbar, S.; Nayeibi, N.; Larijani, B.; Abdollahi, M. A Systematic Review of the Efficacy and Safety of Herbal Medicines Used in the Treatment of Obesity. *World J. Gastroenterol.* **2009**, *15*, 3073–3085. [[CrossRef](#)]
144. Hasani-Ranjbar, S.; Jouyandeh, Z.; Abdollahi, M. A Systematic Review of Anti-Obesity Medicinal Plants—An Update. *J. Diabetes Metab. Disord.* **2013**, *12*, 28. [[CrossRef](#)]
145. Mahdavi, R.; Namazi, N.; Alizadeh, M.; Farajnia, S. *Nigella sativa* Oil with a Calorie-Restricted Diet Can Improve Biomarkers of Systemic Inflammation in Obese Women: A Randomized Double-Blind, Placebo-Controlled Clinical Trial. *J. Clin. Lipidol.* **2016**, *10*, 1203–1211. [[CrossRef](#)] [[PubMed](#)]

146. Mahdavi, R.; Alizadeh, M.; Namazi, N.; Farajnia, S. Changes of Body Composition and Circulating Adipokines in Response to *Nigella sativa* Oil with a Calorie Restricted Diet in Obese Women. *J. Herb. Med.* **2016**, *6*, 67–72. [[CrossRef](#)]
147. Heshmati, J.; Namazi, N.; Memarzadeh, M.R.; Taghizadeh, M.; Kolahdooz, F. *Nigella sativa* Oil Affects Glucose Metabolism and Lipid Concentrations in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. *Food Res. Int.* **2015**, *70*, 87–93. [[CrossRef](#)]
148. Daryabeygi-Khotbehsara, R.; Golzarand, M.; Ghaffari, M.P.; Djafarian, K. *Nigella sativa* Improves Glucose Homeostasis and Serum Lipids in Type 2 Diabetes: A Systematic Review and Meta-Analysis. *Complement. Ther. Med.* **2017**, *35*, 6–13. [[CrossRef](#)]
149. Zaoui, A.; Cherrah, Y.; Mahassini, N.; Alaoui, K.; Amarouch, H.; Hassar, M. Acute and Chronic Toxicity of *Nigella sativa* Fixed Oil. *Phytomedicine* **2002**, *9*, 69–74. [[CrossRef](#)]
150. Le, P.M.; Benhaddou-Andaloussi, A.; Elimadi, A.; Settaf, A.; Cherrah, Y.; Haddad, P.S. The Petroleum Ether Extract of *Nigella sativa* Exerts Lipid-Lowering and Insulin-Sensitizing Actions in the Rat. *J. Ethnopharmacol.* **2004**, *94*, 251–259. [[CrossRef](#)] [[PubMed](#)]
151. Houcher, Z.; Boudiaf, K.; Benboubetra, M.; Houcher, B. Effects of Methanolic Extract and Commercial Oil of *Nigella sativa* L. on Blood Glucose and Antioxidant Capacity in Alloxan-Induced Diabetic Rats. *Pteridines* **2007**, *18*, 8–18. [[CrossRef](#)]
152. Kaplan, S.A.; Meehan, A.G.; Shah, A. The Age Related Decrease in Testosterone Is Significantly Exacerbated in Obese Men With the Metabolic Syndrome. What Are the Implications for the Relatively High Incidence of Erectile Dysfunction Observed in These Men? *J. Urol.* **2006**, *176*, 1524–1528. [[CrossRef](#)]
153. Meddah, B.; Ducroc, R.; El Abbes Faouzi, M.; Eto, B.; Mahraoui, L.; Benhaddou-Andaloussi, A.; Martineau, L.C.; Cherrah, Y.; Haddad, P.S. *Nigella sativa* Inhibits Intestinal Glucose Absorption and Improves Glucose Tolerance in Rats. *J. Ethnopharmacol.* **2009**, *121*, 419–424. [[CrossRef](#)]
154. Badar, A.; Kaatabi, H.; Bamosa, A.; Al-Elq, A.; Abou-Hozafa, B.; Lebda, F.; Alkhadra, A.; Al-Almaie, S. Effect of *Nigella sativa* Supplementation over a One-Year Period on Lipid Levels, Blood Pressure and Heart Rate in Type-2 Diabetic Patients Receiving Oral Hypoglycemic Agents: Nonrandomized Clinical Trial. *Ann. Saudi Med.* **2017**, *37*, 56–63. [[CrossRef](#)]
155. Najmi, A.; Nasiruddin, M.; Khan, R.A.; Haque, S.F. Indigenous Herbal Product *Nigella sativa* Proved Effective as an Antihypertensive in Metabolic Syndrome. *Asian J. Pharm. Clin. Res.* **2013**, *6*, 61–64.
156. Ibrahim, R.M.; Hamdan, N.S.; Mahmud, R.; Imam, M.U.; Saini, S.M.; Rashid, S.N.A.; Abd Ghafar, S.A.; Latiff, L.A.; Ismail, M. A Randomised Controlled Trial on Hypolipidemic Effects of *Nigella sativa* Seeds Powder in Menopausal Women. *J. Transl. Med.* **2014**, *12*, 82. [[CrossRef](#)] [[PubMed](#)]
157. Hosseini, M.S.; Mirkarimi, S.A.; Amini, M.; Mohtashami, R.; Kianbakht, S.; Fallah Huseini, H. Effects of *Nigella sativa* L. Seed Oil in Type II Diabetic Patients: A Randomized, Double-Blind, Placebo—Controlled Clinical Trial. *J. Med. Plants* **2013**, *12*, 93–99.
158. Farzaneh, E.; Nia, F.R.; Mehrtash, M.; Mirmoeini, F.S.; Jalilvand, M. The Effects of 8-Week *Nigella sativa* Supplementation and Aerobic Training on Lipid Profile and VO<sub>2</sub> Max in Sedentary Overweight Females. *Int. J. Prev. Med.* **2014**, *5*, 210–216. [[PubMed](#)]
159. Sethi, G.S.; Dharwal, V.; Naura, A.S. Immunological Basis of Oxidative Stress-Induced Lung Inflammation in Asthma and COPD. In *Oxidative Stress in Lung Diseases: Volume 1*; Springer: Singapore, 2019; Volume 1, pp. 192–223. ISBN 9789811384134.
160. Wahab, S.; Ahmad, I.; Irfan, S.; Siddiqua, A.; Usmani, S.; Ahmad, M.P. Pharmacological Efficacy and Safety of *Glycyrrhiza Glabra* in the Treatment of Respiratory Tract Infections. *Mini-Rev. Med. Chem.* **2021**, *22*, 1476–1494. [[CrossRef](#)] [[PubMed](#)]
161. Lambrecht, B.N.; Hammad, H.; Fahy, J.V. The Cytokines of Asthma. *Immunity* **2019**, *50*, 975–991. [[CrossRef](#)] [[PubMed](#)]
162. Boulet, L.P. Airway Remodeling in Asthma: Update on Mechanisms and Therapeutic Approaches. *Curr. Opin. Pulm. Med.* **2018**, *24*, 56–62. [[CrossRef](#)]
163. Vuolo, F.; Abreu, S.C.; Michels, M.; Xisto, D.G.; Blanco, N.G.; Hallak, J.E.; Zuardi, A.W.; Crippa, J.A.; Reis, C.; Bahl, M.; et al. Cannabidiol Reduces Airway Inflammation and Fibrosis in Experimental Allergic Asthma. *Eur. J. Pharmacol.* **2019**, *843*, 251–259. [[CrossRef](#)] [[PubMed](#)]
164. Chu, E.K.; Drazen, J.M. Asthma One Hundred Years of Treatment and Onward. *Am. J. Respir. Crit. Care Med.* **2005**, *171*, 1202–1208. [[CrossRef](#)] [[PubMed](#)]
165. Ahmad, M.D.F.; Wahab, S.; Ali Ahmad, F.; Intakhab Alam, M.; Ather, H.; Siddiqua, A.; Amir Ashraf, S.; Abu Shaphe, M.; Idreesh Khan, M.; Ali Beg, R. A Novel Perspective Approach to Explore Pros and Cons of Face Mask in Prevention the Spread of SARS-CoV-2 and Other Pathogens. *Saudi Pharm. J.* **2021**, *29*, 121–133. [[CrossRef](#)]
166. Wahab, S.; Annadurai, S.; Abullais, S.S.; Das, G.; Ahmad, W.; Ahmad, M.F.; Kandasamy, G.; Vasudevan, R.; Ali, M.S.; Amir, M. *Glycyrrhiza Glabra* (Licorice): A Comprehensive Review on Its Phytochemistry, Biological Activities, Clinical Evidence and Toxicology. *Plants* **2021**, *10*, 2751. [[CrossRef](#)]
167. Ahmad, M.F.; Ahmad, F.A.; Ashraf, S.A.; Saad, H.H.; Wahab, S.; Khan, M.I.; Ali, M.; Mohan, S.; Hakeem, K.R.; Athar, M.T. An Updated Knowledge of Black Seed (*Nigella sativa* Linn.): Review of Phytochemical Constituents and Pharmacological Properties. *J. Herb. Med.* **2021**, *25*, 100404. [[CrossRef](#)]
168. Balaha, M.F.; Tanaka, H.; Yamashita, H.; Abdel Rahman, M.N.; Inagaki, N. Oral *Nigella sativa* Oil Ameliorates Ovalbumin-Induced Bronchial Asthma in Mice. *Int. Immunopharmacol.* **2012**, *14*, 224–231. [[CrossRef](#)]
169. Noorbakhsh, M.F.; Shaterzadeh-Yazdi, H.; Hayati, F.; Samarghandian, S.; Farkhondeh, T. Protective Effects of Thymoquinone on Pulmonary Disorders in Experimental Studies. *Tanaffos* **2018**, *17*, 211–222. [[PubMed](#)]
170. Saadat, S.; Aslani, M.R.; Ghorani, V.; Keyhanmanesh, R.; Boskabady, M.H. The Effects of *Nigella sativa* on Respiratory, Allergic and Immunologic Disorders, Evidence from Experimental and Clinical Studies, a Comprehensive and Updated Review. *Phyther. Res.* **2021**, *35*, 2968–2996. [[CrossRef](#)]

171. Koshak, A.; Koshak, E.; Heinrich, M. Medicinal Benefits of *Nigella sativa* in Bronchial Asthma: A Literature Review. *Saudi Pharm. J.* **2017**, *25*, 1130–1136. [[CrossRef](#)] [[PubMed](#)]
172. Boskabady, M.H.; Ghasemzadeh Rahbardar, M.; Nemati, H.; Esmailzadeh, M. Inhibitory Effect of *Crocus sativus* (Saffron) on Histamine (H1) Receptors of Guinea Pig Tracheal Chains. *Pharmazie* **2010**, *65*, 300–305. [[CrossRef](#)] [[PubMed](#)]
173. Boskabady, M.H.; Shahabi, M. Bronchodilatory and Anticholinergic Effects of *Nigella sativa* on Isolated Guinea Pig Tracheal Chains. *Iran. J. Med. Sci.* **1997**, *22*, 127–133.
174. Gilani, A.H.; Aziz, N.; Khurram, I.M.; Chaudhary, K.S.; Iqbal, A. Bronchodilator, Spasmolytic and Calcium Antagonist Activities of *Nigella sativa* Seeds (Kalonji): A Traditional Herbal Product with Multiple Medicinal Uses. *J. Pak. Med. Assoc.* **2001**, *51*, 115–120. [[PubMed](#)]
175. Boskabady, M.H.; Mohsenpoor, N.; Takaloo, L. Antiasthmatic Effect of *Nigella sativa* in Airways of Asthmatic Patients. *Phytomedicine* **2010**, *17*, 707–713. [[CrossRef](#)]
176. Boskabady, M.H.; Javan, H.; Sajady, M.; Rakhshandeh, H. The Possible Prophylactic Effect of *Nigella sativa* Seed Extract in Asthmatic Patients (Fundamental and Clinical Pharmacology (2007) 21, 5, (559–566)). *Fundam. Clin. Pharmacol.* **2008**, *22*, 105. [[CrossRef](#)]
177. Kalus, U.; Pruss, A.; Bystron, J.; Jurecka, M.; Smekalova, A.; Lichius, J.J.; Kiesewetter, H. Effect of *Nigella sativa* (Black Seed) on Subjective Feeling in Patients with Allergic Diseases. *Phyther. Res.* **2003**, *17*, 1209–1214. [[CrossRef](#)] [[PubMed](#)]
178. Ciesielska-Figlon, K.; Wojciechowicz, K.; Wardowska, A.; Lisowska, K.A. The Immunomodulatory Effect of *Nigella sativa*. *Antioxidants* **2023**, *12*, 1340. [[CrossRef](#)] [[PubMed](#)]
179. Shahzad, M.; Yang, X.; Raza Asim, M.B.; Sun, Q.; Han, Y.; Zhang, F.; Cao, Y.; Lu, S. Black Seed Oil Ameliorates Allergic Airway Inflammation by Inhibiting T-Cell Proliferation in Rats. *Pulm. Pharmacol. Ther.* **2009**, *22*, 37–43. [[CrossRef](#)] [[PubMed](#)]
180. Ikhsan, M.; Hiedayati, N.; Maeyama, K.; Nurwidya, F. *Nigella sativa* as an Anti-Inflammatory Agent in Asthma. *BMC Res. Notes* **2018**, *11*, 744. [[CrossRef](#)]
181. Islam, M.N.; Hossain, K.S.; Sarker, P.P.; Ferdous, J.; Hannan, M.A.; Rahman, M.M.; Chu, D.T.; Uddin, M.J. Revisiting Pharmacological Potentials of *Nigella sativa* Seed: A Promising Option for COVID-19 Prevention and Cure. *Phyther. Res.* **2021**, *35*, 1329–1344. [[CrossRef](#)] [[PubMed](#)]
182. Almaghasla, D.; Alsayari, A.; Wahab, S.; Motaal, A.A. Knowledge, Attitudes and Practices with Regard to Prophetic Medicine during the COVID-19 Pandemic in Saudi Arabia. *Eur. Rev. Med. Pharmacol. Sci.* **2023**, *27*, 352–358. [[CrossRef](#)] [[PubMed](#)]
183. Abullais, S.S.; Arora, S.; Wahab, S.; Grover, V.; Alshahrani, M.Y.; Shamsudeen, S.M.; Mohammed Asif, S.; Faragalla, A.I.; Elagib, M.F. Convalescent Plasma Therapy against COVID-19: An Update on the Changing Facets of the Ongoing Pandemic. *Curr. Pharm. Biotechnol.* **2023**, *24*, 1515–1523. [[CrossRef](#)]
184. Shoaib, S.; Ansari, M.A.; Kandasamy, G.; Vasudevan, R.; Hani, U.; Chauhan, W.; Alhumaidi, M.S.; Altammar, K.A.; Azmi, S.; Ahmad, W.; et al. An Attention towards the Prophylactic and Therapeutic Options of Phytochemicals for SARS-CoV-2: A Molecular Insight. *Molecules* **2023**, *28*, 795. [[CrossRef](#)] [[PubMed](#)]
185. Niknam, Z.; Jafari, A.; Golchin, A.; Danesh Pouya, F.; Nemati, M.; Rezaei-Tavirani, M.; Rasmi, Y. Potential Therapeutic Options for COVID-19: An Update on Current Evidence. *Eur. J. Med. Res.* **2022**, *27*, 6. [[CrossRef](#)]
186. Vijayvargiya, P.; Esquer Garrigos, Z.; Castillo Almeida, N.E.; Gurram, P.R.; Stevens, R.W.; Razonable, R.R. Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof). *Mayo Clin. Proc.* **2020**, *95*, 1454–1466. [[CrossRef](#)]
187. Silveira, D.; Prieto-Garcia, J.M.; Boylan, F.; Estrada, O.; Fonseca-Bazzo, Y.M.; Jamal, C.M.; Magalhães, P.O.; Pereira, E.O.; Tomczyk, M.; Heinrich, M. COVID-19: Is There Evidence for the Use of Herbal Medicines as Adjuvant Symptomatic Therapy? *Front. Pharmacol.* **2020**, *11*, 1479. [[CrossRef](#)]
188. Khazdair, M.R.; Ghafari, S.; Sadeghi, M. Possible Therapeutic Effects of *Nigella sativa* and Its Thymoquinone on COVID-19. *Pharm. Biol.* **2021**, *59*, 696–703. [[CrossRef](#)] [[PubMed](#)]
189. Shirvani, H.; Rostamkhani, F.; Arabzadeh, E.; Mohammadi, F.; Mohammadi, F. Potential Role of *Nigella sativa* Supplementation with Physical Activity in Prophylaxis and Treatment of COVID-19: A Contemporary Review. *Sport Sci. Health* **2021**, *17*, 849–854. [[CrossRef](#)] [[PubMed](#)]
190. Koshak, A.; Wei, L.; Koshak, E.; Wali, S.; Alamoudi, O.; Demerdash, A.; Qutub, M.; Pushparaj, P.N.; Heinrich, M. *Nigella sativa* Supplementation Improves Asthma Control and Biomarkers: A Randomized, Double-Blind, Placebo-Controlled Trial. *Phyther. Res.* **2017**, *31*, 403–409. [[CrossRef](#)]
191. Barakat, E.M.F.; El Wakeel, L.M.; Hagag, R.S. Effects of *Nigella sativa* on Outcome of Hepatitis C in Egypt. *World J. Gastroenterol.* **2013**, *19*, 2529–2536. [[CrossRef](#)]
192. Onifade, A.A.; Jewell, A.P.; Ajadi, T.A.; Rahamon, S.K.; Ogunrin, O.O. Effectiveness of a Herbal Remedy in Six HIV Patients in Nigeria. *J. Herb. Med.* **2013**, *3*, 99–103. [[CrossRef](#)]
193. Onifade, A.A.; Jewell, A.P.; Adedeji, W.A. *Nigella sativa* Concoction Induced Sustained Seroreversion in HIV Patient. *Afr. J. Tradit. Complement. Altern. Med.* **2013**, *10*, 332–335. [[CrossRef](#)] [[PubMed](#)]
194. Salem, M.L.; Hossain, M.S. Protective Effect of Black Seed Oil from *Nigella sativa* against Murine Cytomegalovirus Infection. *Int. J. Immunopharmacol.* **2000**, *22*, 729–740. [[CrossRef](#)]
195. Oyero, O.G.; Toyama, M.; Mitsuhiro, N.; Onifade, A.A.; Hidaka, A.; Okamoto, M.; Baba, M. Selective Inhibition of Hepatitis c Virus Replication by Alpha-Zam, a *Nigella sativa* Seed Formulation. *African J. Tradit. Complement. Altern. Med.* **2016**, *13*, 144–148. [[CrossRef](#)]

196. Dorra, N.; El-Berrawy, M.; Sallam, S.; Mahmoud, R. Evaluation of Antiviral and Antioxidant Activity of Selected Herbal Extracts. *J. High Inst. Public Health* **2019**, *49*, 36–40. [[CrossRef](#)]
197. Ulasli, M.; Gurses, S.A.; Bayraktar, R.; Yumrutas, O.; Oztuzcu, S.; Igci, M.; Igci, Y.Z.; Cakmak, E.A.; Arslan, A. The Effects of *Nigella sativa* (Ns), *Anthemis hyalina* (Ah) and *Citrus sinensis* (Cs) Extracts on the Replication of Coronavirus and the Expression of TRP Genes Family. *Mol. Biol. Rep.* **2014**, *41*, 1703–1711. [[CrossRef](#)] [[PubMed](#)]
198. Koshak, D.A.E.; Koshak, P.E.A. *Nigella sativa* L as a Potential Phytotherapy for Coronavirus Disease 2019: A Mini Review of in Silico Studies. *Curr. Ther. Res.-Clin. Exp.* **2020**, *93*, 100602. [[CrossRef](#)]
199. Hariton, E.; Locascio, J.J. Randomised Controlled Trials—The Gold Standard for Effectiveness Research: Study Design: Randomised Controlled Trials. *BJOG Int. J. Obstet. Gynaecol.* **2018**, *125*, 1716. [[CrossRef](#)]
200. Kooshki, A.; Tofighiyan, T.; Rastgoo, N.; Rakhshani, M.H.; Miri, M. Effect of *Nigella sativa* Oil Supplement on Risk Factors for Cardiovascular Diseases in Patients with Type 2 Diabetes Mellitus. *Phyther. Res.* **2020**, *34*, 2706–2711. [[CrossRef](#)]
201. Amini, M.; Fallah Huseini, H.; Mohtashami, R.; Sadeqhi, Z.; Ghamarchehre, M.A. Hypolipidemic Effects of *Nigella sativa* L. Seeds Oil in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *J. Med. Plants* **2011**, *10*, 90–94.
202. Rashidmayvan, M.; Mohammadshahi, M.; Seyedian, S.S.; Haghhighizadeh, M.H. The Effect of *Nigella sativa* Oil on Serum Levels of Inflammatory Markers, Liver Enzymes, Lipid Profile, Insulin and Fasting Blood Sugar in Patients with Non-Alcoholic Fatty Liver. *J. Diabetes Metab. Disord.* **2019**, *18*, 453–459. [[CrossRef](#)] [[PubMed](#)]
203. Razmpoosh, E.; Safi, S.; Nadjarzadeh, A.; Fallahzadeh, H.; Abdollahi, N.; Mazaheri, M.; Nazari, M.; Salehi-Abargouei, A. The Effect of *Nigella sativa* Supplementation on Cardiovascular Risk Factors in Obese and Overweight Women: A Crossover, Double-Blind, Placebo-Controlled Randomized Clinical Trial. *Eur. J. Nutr.* **2021**, *60*, 1863–1874. [[CrossRef](#)]
204. Shoaeei-Hagh, P.; Kamelan Kafi, F.; Najafi, S.; Zamanzadeh, M.; Heidari Bakavoli, A.; Ramezani, J.; Soltanian, S.; Asili, J.; Hosseinzadeh, H.; Eslami, S.; et al. A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Benefits of *Nigella sativa* Seeds Oil in Reducing Cardiovascular Risks in Hypertensive Patients. *Phyther. Res.* **2021**, *35*, 4388–4400. [[CrossRef](#)] [[PubMed](#)]
205. Darand, M.; Darabi, Z.; Yari, Z.; Hedayati, M.; Shahrbafe, M.A.; Khoncheh, A.; Hosseini-Ahangar, B.; Alavian, S.M.; Hekmatdoost, A. The Effects of Black Seed Supplementation on Cardiovascular Risk Factors in Patients with Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Phyther. Res.* **2019**, *33*, 2369–2377. [[CrossRef](#)] [[PubMed](#)]
206. Dehkordi, F.R.; Kamkhah, A.F. Antihypertensive Effect of *Nigella sativa* Seed Extract in Patients with Mild Hypertension. *Fundam. Clin. Pharmacol.* **2008**, *22*, 447–452. [[CrossRef](#)] [[PubMed](#)]
207. Qidwai, W.; Hamza, H.B.; Qureshi, R.; Gilani, A. Effectiveness, Safety, and Tolerability of Powdered *Nigella sativa* (Kalonji) Seed in Capsules on Serum Lipid Levels, Blood Sugar, Blood Pressure, and Body Weight in Adults: Results of a Randomized, Double-Blind Controlled Trial. *J. Altern. Complement. Med.* **2009**, *15*, 639–644. [[CrossRef](#)]
208. Bin Sayeed, M.S.; Asaduzzaman, M.; Morshed, H.; Hossain, M.M.; Kadir, M.F.; Rahman, M.R. The Effect of *Nigella sativa* Linn. Seed on Memory, Attention and Cognition in Healthy Human Volunteers. *J. Ethnopharmacol.* **2013**, *148*, 780–786. [[CrossRef](#)]
209. Mahdavi, R.; Namazi, N.; Alizadeh, M.; Farajnia, S. Effects of *Nigella sativa* Oil with a Low-Calorie Diet on Cardiometabolic Risk Factors in Obese Women: A Randomized Controlled Clinical Trial. *Food Funct.* **2015**, *6*, 2041–2048. [[CrossRef](#)] [[PubMed](#)]
210. Namazi, N.; Mahdavi, R.; Alizadeh, M.; Farajnia, S. Oxidative Stress Responses to *Nigella sativa* Oil Concurrent with a Low-Calorie Diet in Obese Women: A Randomized, Double-Blind Controlled Clinical Trial. *Phyther. Res.* **2015**, *29*, 1722–1728. [[CrossRef](#)]
211. Khonche, A.; Huseini, H.F.; Gholamian, M.; Mohtashami, R.; Nabati, F.; Kianbakht, S. Standardized *Nigella sativa* Seed Oil Ameliorates Hepatic Steatosis, Aminotransferase and Lipid Levels in Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind and Placebo-Controlled Clinical Trial. *J. Ethnopharmacol.* **2019**, *234*, 106–111. [[CrossRef](#)] [[PubMed](#)]
212. Safi, S.; Razmpoosh, E.; Fallahzadeh, H.; Mazaheri, M.; Abdollahi, N.; Nazari, M.; Nadjarzadeh, A.; Salehi-Abargouei, A. The Effect of *Nigella sativa* on Appetite, Anthropometric and Body Composition Indices among Overweight and Obese Women: A Crossover, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. *Complement. Ther. Med.* **2021**, *57*, 102653. [[CrossRef](#)] [[PubMed](#)]
213. El Daly, E.S. Protective Effect of Cysteine and Vitamin E, *Crocus sativus* and *Nigella sativa* Extracts on Cisplatin-Induced Toxicity in Rats. *J. Pharm. Belg.* **1998**, *53*, 87–95.
214. Khanna, T.; Zaidi, F.A.; Dandiya, P.C. CNS and Analgesic Studies on *Nigella sativa*. *Fitoterapia* **1993**, *64*, 407–410.
215. Badary, O.A.; Al-Shabanah, O.A.; Nagi, M.N.; Al-Bekairi, A.M.; Elmazar, M.M.A. Acute and Subchronic Toxicity of Thymoquinone in Mice. *Drug Dev. Res.* **1998**, *44*, 56–61. [[CrossRef](#)]
216. Zedlitz, S.; Kaufmann, R.; Boehncke, W.H. Allergic Contact Dermatitis from Black Cumin (*Nigella sativa*) Oil-Containing Ointment. *Contact Dermat.* **2002**, *46*, 188. [[CrossRef](#)]
217. Fallah Huseini, H.; Amini, M.; Mohtashami, R.; Ghamarchehre, M.E.; Sadeqhi, Z.; Kianbakht, S.; Fallah Huseini, A. Blood Pressure Lowering Effect of *Nigella sativa* L. Seed Oil in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Phyther. Res.* **2013**, *27*, 1849–1853. [[CrossRef](#)] [[PubMed](#)]
218. Bamasa, A.O.; Kaatabi, H.; Lebda, F.M.; Al Elq, A.M.; Al-Sultan, A. Effect of *Nigella sativa* Seeds on the Glycemic Control of Patients with Type 2 Diabetes Mellitus. *Indian J. Physiol. Pharmacol.* **2010**, *54*, 344–354.
219. Alsamarai, A.; Abdulsatar, M.; Alobaidi, A. Evaluation of Topical Black Seed Oil in the Treatment of Allergic Rhinitis. *Antiinflamm. Antiallergy Agents Med. Chem.* **2014**, *13*, 75–82. [[CrossRef](#)]

220. Bilal, A.; Masud, T.; Uppal, A.M. BS5-5 Black Seed (*Nigella sativa*) Regulates Glucose, Insulin Level and Lipid Profile in Patients with Type 2 Diabetes. *Diabetes Res. Clin. Pract.* **2008**, *79*, S19–S20. [[CrossRef](#)]
221. Dogar, M.Z.U.H.; Adnan, H.; Akhtar, M.S.; Sheikh, M.A. Preliminary Assessment of Efficacy of *Nigella sativa* Seeds in Acute Lymphoblastic Leukemia in Local Children. *Pharmacologyonline* **2009**, *2*, 769–777.
222. Akhtar, M.S.; Riffat, S. Field Trial of *Saussurea lappa* Roots against Nematodes and *Nigella sativa* Seeds against Cestodes in Children. *J. Pak. Med. Assoc.* **1991**, *41*, 185–187.
223. Al-Jenoobi, F.I.; Al-Thukair, A.A.; Alam, M.A.; Abbas, F.A.; Al-Mohizea, A.M.; Alkharfy, K.M.; Al-Suwayeh, S.A. Effect of Curcuma Longa on CYP2D6- and CYP3A4-Mediated Metabolism of Dextromethorphan in Human Liver Microsomes and Healthy Human Subjects. *Eur. J. Drug Metab. Pharmacokinet.* **2015**, *40*, 61–66. [[CrossRef](#)] [[PubMed](#)]
224. Ali, B.; Amin, S.; Ahmad, J.; Ali, A.; Ali, M.; Mir, S.R. Bioavailability Enhancement Studies of Amoxicillin with Nigella. *Indian J. Med. Res.* **2012**, *135*, 555–559.
225. Vahdati-Mashhadian, N.; Rakhshandeh, H.; Omid, A. An Investigation on LD50 and Subacute Hepatic Toxicity of *Nigella sativa* Seed Extracts in Mice. *Pharm. Int. J. Pharm. Sci.* **2005**, *60*, 544–547.
226. Ahmed, J.H.; Ibraheem, A.Y.; Al-Hamdi, K.I. Evaluation of Efficacy, Safety and Antioxidant Effect of *Nigella sativa* in Patients with Psoriasis: A Randomized Clinical Trial. *J. Clin. Exp. Investig.* **2015**, *5*, 186–193. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.